# **BMJ Open**

# Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomized controlled trials

Journal:	BMJ Open
Manuscript ID:	bmjopen-2015-009128
Article Type:	Research
Date Submitted by the Author:	18-Jun-2015
Complete List of Authors:	Tully, Phillip; University of Adelaide, Discipline of Medicine Baumeister, Harald; University of Freiburg, Rehabilitation Psychology and Psychotherapy, Institute of Psychology; University of Freiburg, Medical Psychology and Medical Sociology
<b>Primary Subject Heading</b> :	Mental health
Secondary Subject Heading:	Cardiovascular medicine, Evidence based practice, Mental health
Keywords:	CARDIOLOGY, MENTAL HEALTH, Depression & mood disorders < PSYCHIATRY, Clinical trials < THERAPEUTICS



1	
2	
3	
4	
5	
5	
6	
7	
8	
à	
10	
10	
11	
12	
13	
11	
14	
15	
16	
17	
18	
10	
19	
20	
21	
22	
23	
$\begin{array}{c} 2\\ 2\\ 3\\ 4\\ 5\\ 6\\ 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 8\\ 9\\ 20\\ 12\\ 23\\ 24\\ 25\\ 26\\ 27\\ 8\\ 9\\ 30\\ 1\\ 32\\ 33\\ 4\\ 35\\ 6\\ 37\\ 8\\ 9\\ 39\\ 33\\ 35\\ 6\\ 37\\ 8\\ 9\\ 39\\ 33\\ 35\\ 6\\ 37\\ 8\\ 9\\ 39\\ 32\\ 33\\ 35\\ 6\\ 37\\ 8\\ 9\\ 39\\ 32\\ 33\\ 35\\ 6\\ 37\\ 8\\ 9\\ 39\\ 32\\ 33\\ 35\\ 6\\ 37\\ 8\\ 9\\ 39\\ 32\\ 32\\ 32\\ 32\\ 32\\ 32\\ 32\\ 32\\ 32\\ 32$	
24	
25	
26	
27	
28	
20	
29	
30	
31	
32	
22	
33	
34	
35	
36	
37	
20	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
51 52	
52	
53	
54	
55	
56	
50	
57	
58	
59	

60

# Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomized controlled trials

Journal for consideration: BMJ Open

Authors: Phillip J. Tully, <sup>1,2</sup> phillip.tully@adelaide.edu.au

> Harald Baumeister<sup>1,3</sup> <u>baumeister@psychologie.uni-freiburg.de</u>

- 1. Department of Rehabilitation Psychology and Psychotherapy, Institute of Psychology, University of Freiburg, Germany
- 2. Freemasons Foundation Centre for Men's Health, Discipline of Medicine, School of Medicine, The University of Adelaide, Australia
- 3. Medical Psychology and Medical Sociology, Faculty of Medicine, University of Freiburg, Germany

#### **Correspondence:**

Harald Baumeister baumeister@psychologie.uni-freiburg.de

Department of Rehabilitation Psychology and Psychotherapy

Institute of Psychology, University of Freiburg

Engelbergerstr. 41, D-79085 Freiburg GERMANY

**Abstract word count:** 293

**Manuscript word count:** 3,214

Tables: 1

Figures: 4

**Key words:** collaborative care; systematic review; randomized controlled trial; depression; coronary heart disease;

#### ABSTRACT

**Objectives:** To systematically review the efficacy of collaborative care for depression in adults with coronary heart disease (CHD) and depression.

**Design:** Systematic review and meta-analysis

Data sources: Electronic databases (Cochrane Central Register of Controlled Trials MEDLINE, EMBASE, PsycINFO and CINAHL) were searched until April 2014 exploding the topics CHD, depression and RCT.

Inclusion criteria: Population, depression comorbid with CHD; intervention, RCT of collaborative care; comparison, either usual care, wait-list control group or no further treatment; and outcome, (primary) major adverse cardiac events (MACE), (secondary) standardized measure of depression, anxiety, quality of life and cost-effectiveness.

Data extraction and analysis: Cochrane Review Manager 5.3 was used to synthesize the data as risk ratios, odds ratios (OR) and standardized mean differences (SMD) with 95% confidence intervals (CI).

**Results:** Sixteen papers met the inclusion criteria and reported six RCTs. The RCTs were comprised by 655 participants randomized to collaborative care and 629 participants randomized to control group (total 1,284). Collaborative depression care did not significantly reduce MACE in the first six months. Small reductions in depressive symptoms were evident in the short term (pooled SMD -0.30; 95% CI -0.41 to -0.19, p < .00001) and depression remission was more likely to be achieved with collaborative care (OR 1.79; 95% CI 1.36 to

#### BMJ Open

2.35, p <.0001). Likewise a significant effect was observed for anxiety symptoms (SMD -.36) and mental quality of life (SMD .24) but not physical quality of life or cost-effectiveness.

**Conclusions:** Collaborative depression care did not lead to a reduction in the primary MACE endpoint. Small effects were observed for depression, depression remission, anxiety and mental quality of life. The cost-effectiveness of collaborative depression care has not been established yet and further research outside of North America is required for the population with CHD.

Review Registration: PROSPERO CRD42014013653

# Strengths

- Protocol based systematic review of randomized controlled trials with a priori defined primary and secondary outcomes
- Exhaustive literature search and additional unpublished data provided by most authors •
- GRADE rating of strength of evidence as moderate

# Limitations

- Substantial heterogeneity observed between studies
- Few studies performed outside of the USA

#### INTRODUCTION

Depression is widely reported to lead to an adverse coronary heart disease (CHD) prognosis [1, 2], poorer quality of life (QOL) [3, 4] and high healthcare costs [5]. Despite ongoing efforts to better identify and treat depression, prior psychological and pharmacological interventions designed especially for the CHD population have reported markedly lower effect sizes than has been observed among other chronic diseases such as diabetes [6, 7]. Moreover, large trials such as the landmark Enhancing Recovery in Coronary Heart Disease (ENRICHD) study [8] did not lead to a significant reduction in major adverse cardiac events (MACE), raising questions about the design [9] and acceptability [10] of depression interventions in the population with CHD.

Collaborative care is emerging as a promising model of healthcare among populations with complex mental health needs [11] and mental disorders comorbid with chronic diseases including diabetes and CHD [12, 13]. Collaborative care is defined by a multi-professional approach to patient care delivered by a primary care physician (PCP) and at least one other health professional, involving a structured patient management plan and interventions, scheduled patient follow-ups, and enhanced inter-professional communication between the multi-professional team [12]. Prior systematic reviews have not reported on the efficacy of CHD studies in particular [14, 15] although mixed CHD and diabetes samples are commonplace [12]. Several large prospective RCT's of collaborative care versus usual care have been reported recently [16-18] making it feasible to examine the efficacy and early benefits of collaborative care, that might in turn assist in the design of subsequent trials and inform clinical practice. This systematic review extends beyond previous studies by reporting the efficacy of collaborative care for depression in adults with comorbid depression and CHD [19].

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

#### **METHODS**

#### **Search Strategy**

This review conformed to the PRISMA guidelines [20] and a protocol has been published elsewhere [19]. Electronic databases were searched without language restrictions until April 2014: the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, MEDLINE, EMBASE, PsycINFO and CINAHL. The search string exploded the topics CHD, depression and RCT, as reported previously [19]. Hand searching reference lists of articles selected for full-text supplemented electronic searches. The principal investigators of studies were contacted to ascertain unpublished data and their knowledge of any other collaborative care trials not included in our primary search. Additional data was provided for five trials [17, 21, 22, 16, 23] and no response was received from the TrueBlue study authors [18].

#### **Inclusion Criteria**

Population: RCT studies performed among adults (18 years and older) with comorbid depression and CHD. Depression defined as depression disorder or clinical depression assessed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) by a standardized interview (e.g. Structured Clinical Interview, Composite International Diagnostic Interview), or a validated self-reports or rating scales with specific cut-off points for depression. Mixed samples (e.g. heart failure, arrhythmia, diabetes) were eligible if  $\geq$  50% of the sample have a CHD diagnosis. Intervention: collaborative care intervention defined as a coordinated model of care involving multidisciplinary healthcare providers, including: (a) at least one health professional (e.g. nurse, psychiatrist, psychologist) in addition to the PCP; (b) a structured patient management

#### **BMJ Open**

plan that delivers either pharmacological or non-pharmacological depression intervention; (c) scheduled patient follow-up; (d) enhanced inter-professional communication between the multiprofessional team. Collaborative care may include usual CHD care or blended depression-CHD care.

Comparison: control group being either (enhanced) usual care, wait-list control group, or no further treatment for comorbid depression-CHD.

Outcomes: Primary; all-cause and CHD-related mortality as well as MACE (e.g. subsequent myocardial infarction, coronary revascularization procedure, incident heart failure, stroke). Secondary; secondary outcomes include depression, anxiety and quality of life (measured either dimensionally or categorically) following the intervention assessed by validated self-report questionnaires or standardized interview. In addition, we considered economic evaluations of health care costs or resource utilization including cost-effectiveness (incremental cost-effectiveness ratio) and cost-utility (quality-adjusted life years).

#### Study Selection Process, Risk of Bias and Assessment

Two reviewers (PJT, HB) independently screened abstracts and articles for eligibility. In the case of title/abstract disagreements, the study was subjected to full-text review and disagreements were resolved by discussion. Two reviewers (PJT, HB) independently assessed included studies using the Cochrane Collaboration's tool for assessing risk of bias [24]. The tool covers sequence generation, allocation concealment, selective outcome reporting and other sources of bias. Adjudication of the strength of evidence for each endpoint was made according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria with GRADE Profiler 3.6.1 [25].

#### Synthesis of Data and Summary Measures

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Standardized mean differences (SMD) for continuous variables, risk ratios (RR) for MACE and odds ratios (OR) for dichotomous endpoints are reported with 95% CI. Data were pooled together with fixed-effects model using the inverse-variance method when heterogeneity was low to moderate ( $I^2 < 60\%$ ), otherwise a random-effects model was used [26, 24]. To evaluate the presence of publication bias, the funnel plot was inspected. All analyses were performed with Review Manager Version 5.3.

#### RESULTS

The search yielded 1,755 citations from which 46 articles were reviewed in detail, 16 papers were retained which reported on 6 RCTs (Figure 1). Five collaborative care trials performed with diabetes and CHD or mixed chronic disease populations were excluded as they did not meet the threshold of more than 50% CHD patients [27, 12, 28-30]. Two trials were close to meeting the definition of collaborative care for depression comorbid with CHD but were excluded. The IDACC [31] study was excluded as the intervention did not initiate pharmacological or non-pharmacological depression treatment and did not involve structured follow-up of participants to augment treatment if necessary. The UPBEAT-UK study [32] was excluded as the intervention was a case-management intervention and did not incorporate other healthcare professionals such as the PCP.

The 6 RCTs that met the inclusion criteria comprised a total of 1,284 patients with comorbid depression and CHD: 655 participants randomized to collaborative care and 629 participants randomized to a control group. A description of the included trials' is shown in Table 1. The median proportion of participants with CHD in the trials was 78.9% suggesting high representative sampling of the chronic disease understudy. The median sample size was 179 participants per study with a median of 47.6% female participants. Four trials recruited

#### **BMJ Open**

participants from multiple sites [33, 10, 34, 35] and two trials were performed at a singlecenter [36, 16]. Five trials were from the United States of America [17, 21, 22, 16, 23] and one trial was performed in Australia [18]. The comparison group was usual care or enhanced usual care in five studies consisting of informing participants' PCP [17, 21, 22, 16, 23] and one trial used a wait-list control group [35].

Depression screening questionnaires varied only minimally. Depression was assessed with the Patient Health Questionnaire (PHQ) to determine study eligibility in 4 trials [22, 16, 18, 23]. Specifically three trials used a two-step screening approach with the PHQ-2 and a PHQ-9 for participants with an initial positive depression response on the PHQ-2 [34, 36, 16]. These trials used a moderate depression threshold consisting of PHQ-9 total scores  $\geq 10$  [34, 36, 16]. The TrueBlue study [35] included patients with mild depression symptoms consisting of PHQ-9 scores  $\geq$  5. In the COPES and CODIACS trials the Beck Depression Inventory (BDI) was used for screening and trial eligibility [10, 33]. The clinical cutoff was set at  $\geq 10$ on at least two different screening occasion's in COPES [10]. In CODIACS [33] the clinical cutoff was set at BDI  $\geq$  10 on at least two different screening occasion's or BDI  $\geq$  15 on 1 occasion. Five of the trials utilizing either the PHQ-9 [35, 36, 16] or Beck Depression Inventory [10, 33] to determine trial eligibility also used the same measure for depression symptom response at the conclusion of the trial. The Bypassing The Blues trial employed the Hamilton Rating Scale for Depression [23] for depression symptom clinical response.

Collaborative care was managed by an allied health team in two trials [33, 10], by nurses in two studies [35, 34] and by social workers in two studies [36, 16]. The collaborative care intervention duration ranged from 3 to 12 months and the median duration was 6 months. The psychotherapy component of the collaborative care package consisted of problem-solving therapy in two studies [10, 33], telephone-delivered manualized CBT in one study [36],

referral to community mental health services in two studies [35, 34], and was mixed in another study [16]. The pharmacological component of the trials varied. In Bypassing The Blues [34] depression pharmacotherapy consisted of citalopram, serotonin norepinephrine reuptake inhibitor or bupropion. In CODIACS [33] depression pharmacotherapy consisted of sertraline, citalopram, or bupropion. In COPES [10] pharmacotherapy consisted of sertraline, escitalopram, venlafaxine, bupropion and mirtazipine. In MOSAIC [36] depression pharmacotherapy consisted of selective serotonin reuptake inhibitor (SSRI, most commonly citalopram), serotonin norepinephrine reuptake inhibitor, bupropion, mirtazapine and anxiety treatment with SSRI or benzodiazepine. In SUCCEED [16] depression pharmacotherapy consisted of SSRI. No specific depression pharmacotherapy regimen was reported in TrueBlue [35].

#### **Risk of Bias**

Risk of bias varied in the included primary trials (eSupplement 1). Missing trial characteristics were common despite all studies having published a trial protocol. In four trials the allocation concealment was unclear. Blinding to subjective endpoints was rated as high in all studies. Selective reporting was noted in three studies because of discrepancies in the study endpoints reported in the protocol by comparison to the primary trial results.

#### **Primary Outcome: Major Adverse Cardiac Events**

Three trials reported 89 MACE in 609 participants in the short to medium term (< 12 months) [23, 17, 37]. Collaborative care was associated with a non-significant reduction in MACE during the short to medium term (RR = 0.62; 95% CI 0.30 to 1.29, p = .20) however there was evidence of substantial moderate heterogeneity ( $I^2 = 66\%$ ) (Fig 2). In the long-term

#### **BMJ Open**

(> 12 months follow-up) only the COPES trial [38] reported MACE with no significant difference between collaborative care and usual care (RR 0.88; 95% CI 0.41 to 1.88, p = .75).

#### **Secondary Outcomes**

Depression Symptoms and Remission

All 6 trials reported change in self-reported depression symptoms by six months postintervention. Collaborative care was associated with a significant reduction in depressive symptoms (pooled SMD –0.30; 95% CI –0.41 to –0.19, p <.00001:  $I^2 = 13\%$ ) (Fig 3). There was no depression symptom data available in the medium or long term. Four trials reported depression remission or clinically significant depression response and additional data was provided by the MOSAIC trial [22]. Collaborative care was significantly associated with depression remission in the short term (OR = 1.79; 95% CI 1.36 to 2.35, p <.0001:  $I^2 = 23\%$ ) (Fig 4). In the medium term only the COPES trial [38] reported depression response based on the BDI  $\leq$  10 (OR 2.26; 95% CI 1.14 to 4.46, p = .02).

#### **Other Secondary Outcomes**

The forest plots for each of the secondary endpoints are reported in eSupplements 2 through 5. Four trials reported anxiety symptom change. It was found that collaborative care led to a small but significant reduction in anxiety symptoms in the short term (SMD -.36; 95% CI -.54 to -.17, p = .0001:  $I^2 = 25\%$ ). Collaborative care was also associated with a significant improvement in mental quality of life in the short term across five trials (SMD .24; 95% CI .11 to .37, p = .0004:  $I^2 = 27\%$ ), while effects for physical QOL were non-significant (SMD 0.11; 95% CI -.03 to .25, p = .12:  $I^2 = .13$ ). In terms of cost-effectiveness, there was no significant benefit afforded by collaborative care based on two trials in the short term (SMD -0.09; 95% CI -0.32 to 0.13, p = .42:  $I^2 = 0\%$ ). Medium term results were reported by Bypassing The Blues [39] which did not indicate significantly lower costs with collaborative care (SMD 0.07; 95% CI -0.22 to 0.35, p = .65).

#### **Ancillary Analyses**

Because there was heterogeneity in the primary MACE endpoint we performed ancillary analysis restricted to acute coronary syndrome hospitalizations, coronary revascularization, heart failure and stroke. There was no significant effect for collaborative care to reduce any of these more specific cardiovascular endpoints (eSupplements 6 through 9). Also, as five trials differentiated between MACE and cardiac-cause hospital readmissions we performed an analysis according to the latter outcome which occurs more frequently. Analysis of 5 trials showed no significant reduction in cardiac-cause hospital readmissions  $(RR = 0.92; 95\% CI 0.73 - 1.15, p = .44; I^2 = 35\%)$  (eSupplement 10).

#### **Sensitivity Analyses**

For depression change, a sensitivity analysis was performed excluding the trials comprised by diabetes patients without CHD [18] and non-depressed CHD patients with anxiety [22]. The sensitivity analysis revealed a small increase in the effect size (pooled SMD -.39; 95% CI -.53 to -.25, p < .00001: I<sup>2</sup> = 0%).

The timing of depression onset [40] and intervention [10] after a cardiac hospitalization has been raised by several scholars as an important methodological consideration. Thus we stratified studies as providing collaborative care immediately upon screening or as an in-patient [36, 16, 35] versus those which considered depression chronicity with a secondary screener at a later stage and as an outpatient [10, 34, 33]. It was found that timing of depression intervention was a source of between-group heterogeneity for depression

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ Open**

severity in six trials (between groups p = .04,  $I^2 = 76.5\%$ ) (eSupplement 11), but not for depression remission (between groups p = .50,  $I^2 = 0\%$  (eSupplement 12).

When analyzing the effect of collaborative care in relation to components of depression treatment, as described in our protocol [19], it was found that collaborative care was not associated with higher prescription rate of antidepressant medication (6 trials, OR = 1.38; 95% CI 0.91 to 2.10, p = .13, I<sup>2</sup> = 62%). There was no increase in the initiation of psychological therapy with collaborative care (6 trials, OR 2.01; 95% CI 0.85 to 4.76, p = .11, I<sup>2</sup> = 84%) (eSupplement 13 and 14).

#### **Publication Bias and GRADE Strength of Recommendations**

For the primary MACE and secondary endpoints we did not find any evidence of publication bias after inspection of the funnel plots (eSupplements 15 and 16). All of the primary and secondary outcomes were graded as moderate strength according to the GRADE criteria [25].

#### DISCUSSION

This systematic review adds to the extant literature by reporting the efficacy and healthcare costs of collaborative care interventions in comorbid depression and CHD populations. It was found that collaborative care was not associated with a significant reduction in MACE in the short term (< 6 months) comparable to other findings with pharmacological or psychological interventions [7, 41]. The results pertaining to the secondary depression endpoints indicated a small albeit significant reduction in depression symptoms with collaborative care, and depression remission was also more likely in the short term. In addition, collaborative care was associated with a significant reduction in anxiety

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

symptoms and an improvement in mental QOL. The findings did not suggest a significant benefit for physical QOL or healthcare costs. Taken together the findings generally support previous systematic reviews regarding more specific depression treatments such as antidepressants or psychotherapy [7, 41].

The absence of a significant reduction in MACE in the short term parallels a prior Cochrane review [7] and other systematic reviews reporting on medical outcomes [42, 43]. However the generalization of these findings is limited as findings were based on only three trials for the primary MACE endpoint in the short term. Thus it is likely that there were simply too few MACE reported resulting in low statistical power. This is further exemplified by comparing the cumulative sample in our analyses to the ENRICHD study [8] which randomized 2,481 myocardial infarction patients to cognitive behavioral therapy supplemented with selective serotonin reuptake inhibitors versus usual care. At 29-month follow-up in the ENRICHD trial there was no difference in event free survival from death or recurrent myocardial infarction (75.8% intervention vs. 75.9% usual care) [8]. The findings of our review align with the general consensus that depression treatment does not lead to a clinically meaningful impact upon cardiovascular events in CHD patients [44-46]. With regards to depression remission, short term results with collaborative care were promising indicating a higher remission rate with collaborative care. However only the COPES trial [38] reported medium term follow-up data. With regards to secondary endpoints of anxiety and mental QOL the results here appear comparable to other systematic reviews on psychological interventions [7].

The limitations of the primary studies are that the predominant collaborative care research has been performed in the United States of America [23, 22, 17, 21, 16] with only one Australian study included here [18]. Other collaborative care trials that did not meet our 

 SBMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from <a href="http://bmjopen.bmj.com/">http://bmjopen.bmj.com/</a> on June 13, 2025 at Agence Bibliographique de l

 of
 Enseignement Superieur (ABES).

 14
 Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

 Page
 Page

#### **BMJ Open**

CHD threshold have been performed in the United Kingdom [27] and The Netherlands [51]. Further trials with CHD populations may assist in clarifying the extent to which collaborative care can be readily applied in other healthcare settings outside the United States of America. As a consequence of low uptake of collaborative care RCTs outside the USA, the total number of RCTs retained for our meta-analysis was low. Nonetheless, Thombs and colleagues' [52] meta-analysis also included only six studies combining efficacy and effectiveness trials evaluating mirtazapine, fluoxetine, sertraline and citalopram, and CBT with adjunctive sertraline. Another limitation was that risk of bias assessment showed that some studies were characterized by methodological limitations, especially a lack of blinding regarding intervention staff and participants (which is not possible in collaborative care interventions when compared to usual care) and blinding of depression assessment (i.e. only self-report instruments used).

In favour of a more comprehensive overview of the topic we included studies with diabetes [18] and anxiety [22]. As shown in sensitivity analyses, this might have underestimated the effect sizes when compared to cardiac-depression populations only. Indeed, evidence for collaborative care appears to be more firmly established in the population with diabetes [42] highlighting discrepancies between depression intervention efficacy in CHD [7, 6]. Given that collaborative care interventions consist of scheduled follow-up it cannot be ruled out that depression efficacy was partly attributable to the attention given to participants in the treatment condition. Further RCTs using attention control groups might also explicate whether treatment effects are partly attributable to time spent with patients.

In conclusion, collaborative depression care in the CHD population did not lead to significant reductions in MACE. Small reductions in depressive symptoms were evident for collaborative care and intervention participants were more likely to achieve depression remission. Small effect sizes for anxiety symptom reduction and improvement in mental QOL were evident with collaborative care. However it remains to be shown that collaborative depression care can lead to sustained reductions in cardiovascular events and a moderate depression response in the longer term. Scant RCT data exists outside of the USA and the cost-effectiveness has not been established at this time.

#### **ACKNOWLEDGEMENTS**

Funding: PJT is supported by the National Health and Medical Research Council of Australia (Neil Hamilton Fairley —Clinical Overseas Fellowship #1053578). The funding body had no role in design or interpretation of the study. The article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding program Open Access Publishing.

We thank the collaborative care trial authors for generously providing additional data required in this review: Prof. Bea Belnap, Prof. Karina Davidson, Prof. Jeff Huffman and Prof. Bruce Rollman. BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

data mining, Al training, and similar technologies

Protected by copyright, including for uses related to text

#### **REFERENCES**

1. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66(6):802-13. doi:10.1097/01.psy.0000146332.53619.b2.

Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129(12):1350-69. doi:10.1161/cir.0000000000000019.
 Samartzis L, Dimopoulos S, Tziongourou M, Nanas S. Effect of psychosocial interventions on quality of life in patients with chronic heart failure: A meta-analysis of randomized controlled trials. Journal of Cardiac Failure. 2013;19(2):125-34.

4. Baumeister H, Hutter N, Bengel J, Härter M. Quality of life in somatically ill persons with comorbid mental disorders: a systematic review and meta-analysis. Psychother Psychosom.

2011;80:275-86. doi:10.1159/000323404.

5. Baumeister H, Haschke A, Munzinger M, Hutter N, Tully PJ. Inpatient and outpatient costs in patients with coronary artery disease and mental disorders: A systematic review.

BioPsychoSocial medicine. 2015;9(11). doi:doi:10.1186/s13030-015-0039-z.

 Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus- a systematic Cochrane review. Diabet Med. 2014. doi:10.1111/dme.12452.

 Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Coch Data Syst Rev. 2011;9:CD008012. doi:10.1002/14651858.CD008012.pub3.

8. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ et al. Effects of treating depression and low perceived social support on clinical events after myocardial

#### **BMJ Open**

infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD)
Randomized Trial. Journal of the American Medical Association. 2003;289(23):3106-16.
9. Linden W. How many meta-analyses does it take to settle a question? Psychosomatic
Medicine. 2013;75(4):332-4. doi:10.1097/PSY.0b013e318295e046.
10. Burg MM, Lesperance F, Reickmann N, Clemow L, Skotzko C, Davidson KW. Treating
persistent depressive symptoms in post-ACS patients: The project COPES Phase-1
randomized controlled trial Contemp Clin Trials. 2008;29(2):231-40.
11. Archer J, Bower P, Gilbody S, Lovell K, Richards D, Gask L et al. Collaborative care for
depression and anxiety problems. Cochrane Database of Systematic Reviews.
2012;10:CD006525. doi:10.1002/14651858.CD006525.pub2.
12. Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B et al.
Collaborative care for patients with depression and chronic illnesses. New England Journal of
Medicine. 2010;363(27):2611-20. doi:10.1056/NEJMoa1003955.
13. Huffman JC, Niazi SK, Rundell JR, Sharpe M, Katon WJ. Essential articles on
collaborative care models for the treatment of psychiatric disorders in medical settings: a
publication by the Academy of Psychosomatic Medicine Research and Evidence-Based
Practice Committee. Psychosomatics. 2014;55:109-22 doi:10.1016/j.psym.2013.09.002.
14. Woltmann E, Grogan-Kaylor A, Perron B, Georges H, Kilbourne AM, Bauer MS.
Comparative effectiveness of collaborative chronic care models for mental health conditions
across primary, specialty, and behavioral health care settings: systematic review and meta-
analysis. Am J Psychiatry. 2012;169(8):790-804. doi:10.1176/appi.ajp.2012.11111616.
15. Watson LC, Amick HR, Gaynes BN, Brownley KA, Thaker S, Viswanathan M et al.
Practice-based interventions addressing concomitant depression and chronic medical
conditions in the primary care setting: a systematic review and meta-analysis. Journal of
primary care & community health. 2013;4(4):294-306. doi:10.1177/2150131913484040.

Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

16. Huffman JC, Mastromauro CA, Sowden GL, Wittmann C, Rodman R, Januzzi JL. A collaborative care depression management program for cardiac inpatients: depression characteristics and in-hospital outcomes. Psychosomatics. 2011;52(1):26-33. doi:10.1016/j.psym.2010.11.021.

17. Davidson KW, Bigger JT, Burg MM, Carney RM, Chaplin WF, Czajkowski S et al. Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. JAMA Internal Medicine. 2013;173(11):997-1004. doi:10.1001/jamainternmed.2013.915.

18. Morgan MA, Coates MJ, Dunbar JA, Reddy P, Schlicht K, Fuller J. The TrueBlue model of collaborative care using practice nurses as case managers for depression alongside diabetes or heart disease: a randomised trial. BMJ open. 2013;3(1). doi:10.1136/bmjopen-2012-002171.

19. Tully PJ, Baumeister H. Collaborative care for the treatment of comorbid depression and coronary heart disease: a systematic review and meta-analysis protocol Systematic Reviews. 2014;3:127.

20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. 21. Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Archives of Internal Medicine. 2010;170(7):600-8. doi:10.1001/archinternmed.2010.29.

22. Huffman JC, Mastromauro CA, Beach SR, Celano CM, Dubois CM, Healy BC et al.

Collaborative care for depression and anxiety disorders in patients with recent cardiac events:

The Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial.

JAMA Intern Med. 2014;174(6):927-36. doi:10.1001/jamainternmed.2014.739.

#### **BMJ Open**

2	
2 3	
4	
5	
6	
7	
2 2	
5 6 7 8 9 10	
9 10	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
11 12 13 14 15 16 17 18 19 20 21 22 23	
22	
22 23 24 25	
24	
25	
26	
27	
28	
29	
29 30	
31	
33	
32 33 34 35	
34	
30	
36	
37 38 39	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
58 59	
60	
00	

23. Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Houck PR, Counihan PJ et al.
Telephone-delivered collaborative care for treating post-CABG depression: a randomized
controlled trial. Journal of the American Medical Association 2009;302(19):2095-103.
doi:10.1001/jama.2009.1670.

24. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, West Sussex, UK: John Wiley & Sons Ltd.; 2008.

25. The GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. . 2013.

26. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med.2002;21(11):1539-58. doi:10.1002/sim.1186.

27. Coventry P, Lovell K, Dickens C, Bower P, Chew-Graham C, McElvenny D et al.

Integrated primary care for patients with mental and physical multimorbidity: cluster

randomised controlled trial of collaborative care for patients with depression comorbid with

diabetes or cardiovascular disease. BMJ. 2015;350:h638. doi:10.1136/bmj.h638.

28. Bogner HR, de Vries HF. Integration of Depression and Hypertension Treatment: A Pilot, Randomized Controlled Trial. The Annals of Family Medicine. 2008;6(4):295-301.

doi:10.1370/afm.843.

29. Stewart JC, Perkins AJ, Callahan CM. Effect of Collaborative Care for Depression on Risk of Cardiovascular Events: Data From the IMPACT Randomized Controlled Trial. Psychosomatic Medicine. 2014;76(1):29-37. doi:10.1097/psy.00000000000022.

30. Vera M, Perez-Pedrogo C, Huertas SE, Reyes-Rabanillo ML, Juarbe D, Huertas A et al.

Collaborative Care for Depressed Patients With Chronic Medical Conditions: A Randomized

Trial in Puerto Rico. Psychiatric services (Washington, DC). 2010;61(2):144-50.

doi:10.1176/appi.ps.61.2.144.

31. Cheok F, Schrader G, Banham D, Marker J, Hordacre AL. Identification, course, and treatment of depression after admission for a cardiac condition: rationale and patient

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

characteristics for the Identifying Depression As a Comorbid Condition (IDACC) project. American Heart Journal. 2003;146(6):978-84.

32. Tylee A, Haddad M, Barley E, Ashworth M, Brown J, Chambers J et al. A pilot randomised controlled trial of personalised care for depressed patients with symptomatic coronary heart disease in South London general practices: the UPBEAT-UK RCT protocol and recruitment. BMC Psychiatry. 2012;12:58. doi:http://dx.doi.org/10.1186/1471-244X-12-58.

33. Whang W, Burg MM, Carney RM, Freedland KE, Bigger JT, Catellier D et al. Design and baseline data from the vanguard of the Comparison of Depression Interventions after Acute Coronary Syndrome (CODIACS) randomized controlled trial. Contemp Clin Trials. 2012;33(5):1003-10. doi:10.1016/j.cct.2012.05.005.

34. Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Schulberg HC, Reynolds CF,
3rd. The Bypassing the Blues treatment protocol: stepped collaborative care for treating postCABG depression. Psychosom Med. 2009;71(2):217-30. doi:PSY.0b013e3181970c1c [pii]

10.1097/PSY.0b013e3181970c1c [doi].

35. Morgan M, Dunbar JA, Reddy P, Coates M, Leahy R. The TrueBlue study: Is practice nurse-led collaborative care effective in the management of depression for patients with heart disease or diabetes? BMC Family Practice. 2009;10(1):46.

36. Huffman JC, Beach SR, Suarez L, Mastromauro CA, Dubois CM, Celano CM et al.Design and baseline data from the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized controlled trial. Contemp Clin Trials. 2013.

doi:10.1016/j.cct.2013.09.012.

37. Ladapo JA, Shaffer JA, Fang Y, Ye S, Davidson KW. Cost-effectiveness of enhanced depression care after acute coronary syndrome: Results from the coronary psychosocial

#### **BMJ Open**

evaluation studies randomized controlled trial. Archives of Internal Medicine. 2012;172(21):1682-4. doi:10.1001/archinternmed.2012.4448. 38. Ye S, Shaffer JA, Rieckmann N, Schwartz JE, Kronish IM, Ladapo JA et al. Long-term outcomes of enhanced depression treatment in patients with acute coronary syndromes. Am J Med. 2014;127(10):1012-6. doi:10.1016/j.amjmed.2014.05.004. 39. Donohue JM, Belnap BH, Men A, He F, Roberts MS, Schulberg HC et al. Twelve-month cost-effectiveness of telephone-delivered collaborative care for treating depression following CABG surgery: a randomized controlled trial. General Hospital Psychiatry. 2014;36(5):453-9. 40. Parker GB, Hilton TM, Walsh WF, Owen CA, Heruc GA, Olley A et al. Timing is everything: the onset of depression and acute coronary syndrome outcome. Biol Psychiatry. 2008;64(8):660-6. 41. Whalley B, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Int J Behav Med. 2014;21(1):109-21. doi:10.1007/s12529-012-9282-x. 42. Huang Y, Wei X, Wu T, Chen R, Guo A. Collaborative care for patients with depression and diabetes mellitus: a systematic review and meta-analysis. BMC Psychiatry. 2013;13(1):1-11. doi:10.1186/1471-244X-13-260. 43. Ekers D, Murphy R, Archer J, Ebenezer C, Kemp D, Gilbody S. Nurse-delivered collaborative care for depression and long-term physical conditions: A systematic review and meta-analysis. Journal of Affective Disorders. 2013;149(1-3):14-22. doi:http://dx.doi.org/10.1016/j.jad.2013.02.032. 44. Dickens C, Cherrington A, Adeyemi I, Roughley K, Bower P, Garrett C et al. Characteristics of psychological interventions that improve depression in people with coronary heart disease: a systematic review and meta-regression. Psychosom Med.

2013;75(2):211-21. doi:10.1097/PSY.0b013e31827ac009.

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

45. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. American Journal of Cardiology. 2011;107(7):972-9. doi:10.1016/j.amjcard.2010.11.017. 46. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. Journal of the American College of Cardiology. 2006;48(8):1527-37. doi:http://dx.doi.org/10.1016/j.jacc.2006.06.055.

47. Banankhah SK, Friedmann E, Thomas S. Effective treatment of depression improves postmyocardial infarction survival. World journal of cardiology. 2015;7(4):215-23.

doi:10.4330/wjc.v7.i4.215.

48. Scherrer JF, Chrusciel T, Garfield LD, Freedland KE, Carney RM, Hauptman PJ et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry. 2012;200(2):137-42. doi:10.1192/bjp.bp.111.096479. 49. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792-8.

doi:10.1001/archpsyc.62.7.792.

50. Saab PG, Bang H, Williams RB, Powell LH, Schneiderman N, Thoresen C et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. J Psychosom Res. 2009;67(1):45-56. doi:10.1016/j.jpsychores.2009.01.015.

51. van Dijk SE, Pols AD, Adriaanse MC, Bosmans JE, Elders PJ, van Marwijk HW et al. Cost-effectiveness of a stepped-care intervention to prevent major depression in patients with type 2 diabetes mellitus and/or coronary heart disease and subthreshold depression: design of a cluster-randomized controlled trial. BMC Psychiatry. 2013;13:128.

doi:http://dx.doi.org/10.1186/1471-244X-13-128.

#### **BMJ Open**

52. Thombs BD, de Jonge P, Coyne JC, Whooley MA, Frasure-Smith N, Mitchell AJ et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. Journal of American Medical Association. 2008;300(18):2161-71. doi:10.1001/jama.2008.667.
53. Kronish IM, Rieckmann N, Burg MM, Edmondson D, Schwartz JE, Davidson KW. The effect of enhanced depression care on adherence to risk-reducing behaviors after acute coronary syndromes: findings from the COPES trial. Am Heart J. 2012;164(4):524-9. doi:10.1016/j.ahj.2012.07.024.
54. Beach SR, Januzzi JL, Mastromauro CA, Healy BC, Beale EE, Celano CM et al. Patient health questionnaire-9 score and adverse cardiac outcomes in patients hospitalized for acute cardiac disease. Journal of Psychosomatic Research. 2013;75:409-13.

doi:http://dx.doi.org/10.1016/j.jpsychores.2013.08.001.

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

to text

data mining, Al training, and similar technologies

Protected by copyright, including for uses related

# Table 1. Characteristics of included collaborative care studies in the treatment of


## comorbid depression and coronary heart disease

	COL	norbid dep	ression and c	oronary heart o	lisease	
Study, Country	Design and Intervention Length	CHD population (% CHD in total sample)	Sample Size of CC vs. UC (% females in total sample)	Depression Assessment	Collaborative Care Intervention	Control Group
Bypassing The Blues, Rollman t al. 2009, USA 23, 34, 39]	Single-blind effectiveness RCT, 8 months	CABG (100%)	150 CC vs. 152 UC (41.4)	PHQ-2 positive screen as an inpatient and PHQ-9 score ≥ 10 2 weeks post-CABG, PRIME-MD for mood disorders	Structured telephone f/up, patient preferences for depression care, psychoeducation, bibliotherapy, promoting adherence, and initiation or adjustment of antidepressant pharmacotherapy provided by PCP (citalopram, SNRI or bupropion); referral to a community MHS; a combination of the above; "watchful-waiting"	Usual care, given brochure on depression and heart disease, PCP informed of depression status
DDIACS, avidson et al. SA [33, 17]	Single-blind effectiveness RCT, 6 months	UA, MI (100%)	73 CC vs. 77 UC (42.0)	BDI-I score $\geq$ 10 on 2 screening occasions or $\geq$ 15 on 1 occasion 2 to 6 months after hospitalization	Initial patient preference for problem-solving therapy and/or pharmacotherapy (sertraline, citalopram, buproprion), or neither, then a stepped-care approach every 6-8 weeks, structured f/up initially every week with PST or 1-2 and 3 - 5 weeks to titrate doses with pharmacotherapy, study team included a site physician and fed back information to PCP	Usual care, locally administered, ad libitum depression care, PCP informed of depression status
DPES, avidson et al. 1, 38, 10, 37, ]	Single-blind effectiveness RCT, 6 months	UA, MI (100%)	80 CC vs. 77 UC (53.5)	BDI-I score ≥ 10 on 2 screening occasions 1 week and 3 months after hospitalization	Initial patient preference for problem-solving therapy and/or pharmacotherapy (sertraline, escitalopram, venlafaxine, bupropion, mirtazapine), then a stepped-care approach, repeated	Usual care, locally administered, ad libitum depression care, PCP informed of depression status


					assessments and augmentation if required at 8 week intervals, structured f/up initially every week with PST or 1-2 and $3 - 5$ weeks to titrate doses with pharmacotherapy, study team included a site physician and fed back information to PCP	
MOSAIC, Huff man et al., USA [36, 22]	Single-blind effectiveness RCT, 6 months	UA, MI, HF, arrhythmia (51%)	92 CC vs. 91 EUC (53.0)	Two-step screening process; PHQ-2, GAD-2 and item about panic attacks as an inpatient and PRIME-MD for depression, GAD and PD	Social worker and psychiatrist developed individualized treatment recommendations; patient preference for pharmacotherapy (SSRI most commonly citalopram, SNRI, bupropion, mirtazapine and anxiety treatment with SSRI or benzodiazepine) or CBT (min. six session CBT when allocated); stepped- care; PCP informed of patient preference; structured telephone call and f/up to monitor symptoms, promote adherence and engagement;	Enhanced usual care, PCP informe of psychiatric status at baseline and subsequent screening
SUCCEED Huffman et al 2011, USA [16, 54]	Single-blind effectiveness RCT, 3 months	UA, MI, HF, arrhythmia (52.6%)	90 CC vs. 85 UC (48.6)	Two-step screening process; PHQ-2 positive screen and PHQ-9 score ≥ 10 as an inpatient	Social worker and psychiatrist individualized depression treatment recommendations based on history and patient preference (SSRI or psychotherapy); study team provided the PCP or cardiologist with treatment recommendations; verbal and written recommendations to the inpatient treatment team; depression education for pleasant activities scheduling; monitored for	Usual care, PCP informe of depression status

					adequate depression	
					response;	
TrueBlue,	Cluster	CHD and	170 CC vs.	PHQ-9 score $\geq$	Scheduled visits to	Usual care,
Morgan et al.,	randomized	diabetes	147 WLC	5 as a primary	PN and PCP every 3	PN monitor
AUS [35, 18]	RCT, 12	(57.8)	(46.7)	care patient	months over 12-	depression by
	months				months; referrals to	screening at
					MHS; development	scheduled
					and recording of	intervals
					patient goals;	

BDI-I; Beck Depression Inventory-I; CABG, coronary artery bypass graft; CC, collaborative care; CHD, coronary heart disease; COPES, Coronary Psychosocial Evaluation Studies; CODIACS, Centralized, Stepped, Patient Preference–Based Treatment for Patients With Post–Acute Coronary Syndrome Depression; GAD, generalized anxiety disorder; HF, heart failure; MHS, mental health services; MI, myocardial infarction; MOSAIC, Management of Sadness and Anxiety in Cardiology; PCP, primary care physician; PD, panic disorder; PHQ, Patient Health Questionnaire; PN, practice nurse; PRIME-MD, Primary Care Evaluation of Mental Disorders; PST, problem-solving therapy; RCT, randomized controlled trial; SSRI, selectoive serotonin reuptake inhibitors; SNRI, serotonin norepinephrine reuptake inhibitor; SUCCEED, Screening Utilization and re Effectru Collaborative Care for More Effective and Efficient Treatment of Depression; UA, unstable angina; WLC, waitlist control:



BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



# risk r. medium ter. Fig 2. Forest plot showing the risk ratio for MACE post intervention in collaborative care studies versus usual care or waiting list control (short and

1 2 3	
4 5 6	
7 8 9 10	
10 11 12 13	
14 15 16	
17 18 19	
20 21 22	
23 24 25 26	
26 27 28 29	
30 31 32	
33 34 35	
36 37 38 39	
40 41 42	
43 44 45	
46 47 48 49	
49 50 51 52	
53 54 55	
56 57 58	
59 60	

	Collat	oorative C	are		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.2.1 Short Term									
Bypass The Blues 2009	-7.6	7.3485	150	-4.5	7.3973	152	23.5%	-0.42 [-0.65, -0.19]	<b>_</b>
CODIACS 2013	-10.1	8.1434	73	-6.6	8.3711	77	11.7%	-0.42 [-0.75, -0.10]	
COPES 2010	-5.7	8.5378	80	-1.9	8.3711	77	12.2%	-0.45 [-0.76, -0.13]	
MOSAIC 2014	-8.06	6.9364	91	-6.01	6.9364	92	14.4%	-0.29 [-0.59, -0.00]	
SUCCEED 2011	-8.67	7.1618	90	-6.9	6.027	85	13.8%	-0.27 [-0.56, 0.03]	
TrueBlue 2013 Subtotal (95% CI)	-3.6	10.245	164 648	-2.6	10.8747	146 629	24.5% 100.0%	-0.09 [-0.32, 0.13] - <b>0.30 [-0.41, -0.19]</b>	•
Heterogeneity: Chi² = 5.73	8, df = 5 (F	e = 0.33);	I <sup>z</sup> = 13%	6					
Test for overall effect: Z = \$	5.39 (P <	0.00001)							
									-1 -0.5 0 0.5

depressi care or wait. Fig 3. Forest plot showing depressive symptoms in collaborative care studies versus

	Collaborative	Care	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
1.1.1 Short term							
Bypass The Blues 2009	75	150	45	152	29.2%	2.38 [1.48, 3.82]	<b>_</b>
CODIACS 2013	38	73	37	77	22.6%	1.17 [0.62, 2.23]	
COPES 2010	34	80	19	77	14.5%	2.26 [1.14, 4.46]	<b>_</b>
IOSAIC 2014	19	55	9	47	8.3%	2.23 [0.89, 5.56]	
SUCCEED 2011 Subtotal (95% CI)	44	90 <b>448</b>	37	85 <b>438</b>	25.4% 100.0%	1.24 [0.68, 2.25] 1.79 [1.36, 2.35]	•
Total events	210		147				
Heterogeneity: Chi <sup>2</sup> = 5.17	7. df = 4 (P = 0.2	7); I <b>²</b> = 23	3%				
Test for overall effect: Z =	4.14 (P < 0.0001	D.					
1.1.2 Medium term							
	34	80 <mark>80</mark>	19	77 77	100.0% 100.0%	2.26 [1.14, 4.46] 2.26 [1.14, 4.46]	
COPES 2010 <b>Subtotal (95% CI)</b> Total events	34 34		19 19				-
Subtotal (95% CI)	34						
Subtotal (95% CI) Total events	34 able						
Subtotal (95% CI) Fotal events Heterogeneity: Not applic:	34 able						
Subtotal (95% CI) Fotal events Heterogeneity: Not applic:	34 able						

Fig 4. Forest plot showing depression remission in collaborative care studies versus usual care or waiting list control (short and medium term)

#### **BMJ Open**




Figure showing the adjudication of risk of bias in included trials. Risk of bias independently adjudicated by PJT and HB using Cochrane Review Manager 5.3. Final risk of bias determined by consensus between the two raters.

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## eSupplement 2. Forest plot showing anxiety symptoms in collaborative care studies versus usual care or waiting list control (short term)

		-			
tudy or Subgroup	Experimental Mean SD Tota	Control al Mean SD Tot		d. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% CI
ODIACS 2013	-7.06 9.6081 6	32 -3.92 8.3874 6	2 20.7%	-0.35 [-0.70, 0.01]	
OPES 2010 OSAIC 2014			7 24.2% 1 28.0%	-0.63 [-0.95, -0.31] -0.23 [-0.52, 0.06]	
UCCEED 2011			15 27.1%	-0.25 [-0.55, 0.05]	
otal (95% CI)	32	4 3	5 100.0%	-0.36 [-0.54, -0.17]	•
eterogeneity: Tau² =		= 3 (P = 0.26); I <sup>2</sup> = 25%			-1 -0.5 0 0.5 1
est for overall effect:	Z = 3.84 (P = 0.0001)				Favours Collab. Care Favours Control
. confidence	interval; IV, in	nverse varianc	2;		
,			,		

# eSupplement 3. Forest plot showing mental quality of life symptoms in collaborative care studies versus usual care or waiting list control (short term)

tudy or Subgroup	Ex	perimental SD	Total		Control	Total	Weight	Std. Mean Difference IV, Fixed, 95% Cl	Std. Mean D	
ypass The Blues 2009		12.2474	150		12.3288	152	32.9%	0.26 [0.03, 0.49]	10,11XCU,	-
ODIACS 2013		13.1564	65		14.0076	70	14.8%	0.09 [-0.25, 0.43]		-
OPES 2010		11.4735	59		12.5511	65	13.6%	-0.04 [-0.39, 0.31]		_
OSAIC 2014	11.21	12.2164	92	5.53	12.2164	91	19.6%	0.46 [0.17, 0.76]		
UCCEED 2011	12.18	15.2784	90	8.26	13.1204	85	19.1%	0.27 [-0.02, 0.57]	t	•
otal (95% Cl) leterogeneity: Chi² = 5.45	5 df - 4 (	P = 0.24)· P	456			463	100.0%	0.24 [0.11, 0.37]		•
est for overall effect: Z = 3			- 27%	,					-1 -0.5 Ó Favours Control	0.5 1 Favours Collab. Care
I, confidence in	iterva	l; IV, i	nver	se va	iriance	2:				
, confidence in	iier va	<i>, , , , , ,</i>	aver,		ii iunice	-,				

# eSupplement 4. Forest plot showing physical quality of life symptoms in collaborative care studies versus usual care or waiting list control (short term)

	Ex	perimenta	l.		Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Bypass The Blues 2009	12.8	9.798	150	11.1	9.8631	152	30.5%	0.17 [-0.05, 0.40]	
CODIACS 2013	-0.78	10.735	65	-1.04	11.5752	70	15.4%	0.02 [-0.31, 0.36]	
COPES 2010	1.44	9.7261	65	-1.01	9.8875	65	14.8%	0.25 [-0.10, 0.59]	
MOSAIC 2014	4.88	9.8353	92	2.57	9.8353	91	20.0%	0.23 [-0.06, 0.52]	
SUCCEED 2011	2.14	11.6975	90	3.88	12.7958	85	19.3%	-0.14 [-0.44, 0.16]	
Total (95% CI)			462			463	100.0%	0.11 [-0.03, 0.25]	•
Heterogeneity: Tau <sup>2</sup> = 0.00	; Chi <sup>2</sup> =	4.62, df =	4 (P = 0)	.33); 12:	= 13%				
	est for overall effect: $Z = 1.57$ (P = 0.12)							-1 -0.5 0 0.5 Favours Control Favours Collab. Care	


Cl, confidence interval; IV, inverse variance;

# eSupplement 5. Forest plot showing healthcare costs in collaborative care studies versus usual care or waiting list control (short term and medium term)

	E	xperimental			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
5.3.1 Short Term									
CODIACS 2013	4,289	8,026.8694	73	4,358	8,026.8694	77	48.9%	-0.01 [-0.33, 0.31]	
COPES 2010	1,857	5,471.3714	80	2,797	5,471.3714	77	51.1%	-0.17 [-0.48, 0.14]	
Subtotal (95% CI)			153			154	100.0%	-0.09 [-0.32, 0.13]	
Heterogeneity: Chi <sup>2</sup> = 0.50	J, df = 1 (P	$= 0.48$ ; $ ^2 = 0$	9%						
Test for overall effect: Z = 0	0.80 (P = (	0.42)							
5.3.2 Medium Term									
Bypass The Blues 2009	19,279	31,369		17,522	21,072	99	100.0%	0.07 [-0.22, 0.35]	
Subtotal (95% CI)			90			99	100.0%	0.07 [-0.22, 0.35]	
	oblo								
Heterogeneity: Not applica	anie								
Heterogeneity: Not applica Test for overall effect: Z = 0		0.65)							
		D.65)							
		0.65)							-1 -0.5 0 0.5


CI, confidence interval; IV, inverse variance;

# eSupplement 6. Forest plot showing the risk ratio for acute coronary syndrome post intervention in collaborative care studies versus usual care or waiting list control (short term)



*CI*, confidence interval; *IV*, inverse variance; 

# eSupplement 7. Forest plot showing the risk ratio for coronary revascularization post intervention in collaborative care studies versus usual care or waiting list control (short term)



CI, confidence interval; IV, inverse variance;

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

data mining,

, Al training, and similar technologies


Protected by copyright, including for uses related to text and

### eSupplement 8. Forest plot showing the risk ratio for heart failure post intervention in collaborative care studies versus usual care or waiting list control (short term)

	Experimental Control		Experimental Control			<b>Risk Ratio</b>	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Bypass The Blues 2009	6	150	11	152	67.1%	0.55 [0.21, 1.46]	
CODIACS 2013	2	73	3	77	20.3%	0.70 [0.12, 4.09]	
COPES 2010	1	80	3	77	12.5%	0.32 [0.03, 3.02]	
Total (95% CI)		303		306	100.0%	0.54 [0.25, 1.20]	-
Total events	9		17				
Heterogeneity: Chi <sup>2</sup> = 0.30	, df = 2 (P =	0.86);	l² = 0%				0.02 0.1 1 10 50
Test for overall effect: Z = 1	1.51 (P = 0.	13)					0.02 0.1 1 10 50 Favours Collab. Care Favours Control


CI, confidence interval; IV, inverse variance;

# eSupplement 9. Forest plot showing the risk ratio for stroke post intervention in collaborative care studies versus usual care or waiting list control (short term)




; inverse . *CI, confidence interval; IV, inverse variance;* 

# eSupplement 10. Forest plot showing the risk ratio for cardiac-cause hospital admission post intervention in collaborative care studies versus usual care or waiting list control (short term)



CI, confidence interval; IV, inverse variance;

# eSupplement 11. Forest plot of sensitivity analysis showing depression symptoms post intervention in collaborative care studies versus usual care or waiting list control (short term)



## eSupplement 12. Forest plot of sensitivity analysis showing depression remission post intervention in collaborative care studies versus usual care or waiting list control (short term)

	Collaborative Care	Control		Odds Ratio	Odds Ratio
Study or Subgroup			Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.9.1 Treatment Initiated		-			_
MOSAIC 2014	19 55	9 47	31.7%	2.23 [0.89, 5.56]	
SUCCEED 2011	44 90	37 85	68.3%	1.24 [0.68, 2.25]	
Subtotal (95% CI)	145	132	100.0%	1.49 [0.88, 2.55]	
Fotal events	63	46			
Heterogeneity: Tau <sup>2</sup> = 0.0	2; Chi <sup>2</sup> = 1.11, df = 1 (P =	= 0.29); I <sup>2</sup> = 10%			
Test for overall effect: Z =	1.47 (P = 0.14)				
1.9.2 Treatment Initiated	After Confirming Chron	nicity			
Bypass The Blues 2009	75 150	45 152	42.5%	2.38 [1.48, 3.82]	
CODIACS 2013	38 73	37 77	29.9%	1.17 [0.62, 2.23]	
COPES 2010	34 80	19 77	27.6%	2.26 [1.14, 4.46]	
Subtotal (95% CI)	303		100.0%	1.90 [1.23, 2.93]	
Fotal events	147	101		tree [ tree, mool	
leterogeneity: Tau <sup>2</sup> = 0.0		= 0.20); 1* = 39%			
fest for overall effect: Z =	2.00 (r = 0.004)				
					0.2 0.5 1 2 5
Fest for subgroup differer	nces; Chi² = 0.46. df = 1	(P = 0.50). I <sup>2</sup> = 0.	%		Favours Control Favours Collab. Care
	and a second sec				

# eSupplement 13. Forest plot showing the odds ratio for anti-depressant therapy post intervention in collaborative care studies versus usual care or waiting list control (short term)


	Collaborative Care		e Care Control		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Bypass The Blues 2009	55	126	40	127	19.4%	1.68 [1.01, 2.82]	
CODIACS 2013	37	73	28	77	16.5%	1.80 [0.94, 3.45]	
COPES 2010	38	80	23	77	16.4%	2.12 [1.10, 4.09]	
MOSAIC 2014	36	53	28	46	13.3%	1.36 [0.60, 3.11]	
SUCCEED 2011	47	70	39	68	15.7%	1.52 [0.76, 3.04]	
TrueBlue 2013	34	162	36	113	18.7%	0.57 [0.33, 0.98]	
Total (95% CI)		564		508	100.0%	1.38 [0.91, 2.10]	
Total events	247		194				
Heterogeneity: Tau <sup>2</sup> = 0.17	7; Chi <sup>2</sup> = 13.00,	df = 5 (P	= 0.02);	²= 629	6		0.2 0.5 1 2 5
Test for overall effect: Z = 1	1.51 (P = 0.13)						Favours Control Favours Collab. Care

Cl, confidence interval; IV, inverse variance;

### eSupplement 14. Forest plot showing the odds ratio for psychotherapy post intervention in collaborative care studies versus usual care or waiting list control (short term)

	Collaborative	Care Control			Collaborative Care Control O				Odds Ratio	Odds Ratio
Study or Subgroup	Events Total		Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI			
Bypass The Blues 2009	5 126		7	127	14.6%	0.71 [0.22, 2.29]				
CODIACS 2013	48	73	14	77	17.4%	8.64 [4.06, 18.37]				
COPES 2010	31	80	9	77	16.9%	4.78 [2.09, 10.94]				
MOSAIC 2014	40	53	34	46	16.4%	1.09 [0.44, 2.69]				
SUCCEED 2011	14	70	19	68	17.2%	0.64 [0.29, 1.42]				
TrueBlue 2013	37	162	11	109	17.6%	2.64 [1.28, 5.43]	—•—			
Fotal (95% CI)		564		504	100.0%	2.01 [0.85, 4.76]				
Fotal events	175		94							
Heterogeneity: Tau <sup>2</sup> = 0.97	7; Chi <sup>2</sup> = 31.40,	df = 5 (P	< 0.0000	)1); I <sup>2</sup> =	84%		0.05 0.2 1 5 20			
Fest for overall effect: Z = 1	1.59 (P = 0.11)						Favours Control Favours Collab. Care			

*CI*, *confidence interval*; *IV*, *inverse variance*;




Funnel showing the publication bias in the MACE endpoint. Primary study results are plotted as RR on the x axis by SE of the logRR on the y-axis.

MACE, major adverse cardiac events; RR, risk ratio; SE, standard error;

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.





Funnel showing the publication bias in depression symptom change endpoint. Primary study results are plotted as SMD on the x axis by SE of the SMD on the y-axis.

SE, standard error; SMD, standardized mean difference

1 2 3 4 5 6	
6 7 8 9 10	
7 8 9 10 11 12 13 14 15 16 17 18	
19	
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	
27 28 29 30 31	
32 33 34 35 36	
39 40 41	
42 43 44 45 46	
47 48 49 50 51 52	
52 53 54 55 56 57	
58 59 60	

eSupplement 17	GRADE a	assessment of	each	endpoint
----------------	---------	---------------	------	----------

GRADE Item	MACE	Depression	Anxiety	Mental	Physical	Cost
	Endpoint			QOL	QOL	Effectiveness
Risk of bias	Serious (-1)					
Inconsistency	No	No	No	No	No	No
Indirectness	No	No	No	No	No	No
Imprecision	No	No	No	No	No	No
Publication bias	Undetected	Undetected	Undetected	Undetected	Undetected	Undetected
Large effect	No	No	No	No	No	No
Plausible confounding would change the effect	No	No	No	No	No	No
Dose response gradient	No	No	No	No	No	No
Quality of evidence	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate

GRADE assessment made using GRADE profiler 3.6.1 [27]

*MACE included myocardial infarction, coronary revascularization procedure, incident heart failure, stroke* 

MACE, major adverse cardiac events; QOL, quality of life



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6 and abstract
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6 - 7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	eSupplemer 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	8

Page 51 of 52



Λ

# PRISMA 2009 Checklist

4 5 Section/topic 6	#	Checklist item	Reported on page #				
7 Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	10				
10 Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	NA				
14 Study selection 15	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8, Fig 1				
1 <sup>6</sup> Study characteristics 17 18	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8-10, Table 1				
19 Risk of bias within studies 20 21	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10, eSupplement 1				
22 Results of individual studies 23 24	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Fig 2 - 4				
25 25 Synthesis of results 26	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10 - 13 Fig 2 – 4;				
27 Risk of bias across studies 28 29	22	Present results of any assessment of risk of bias across studies (see Item 15).	10, eSupplement 1				
30 31 Additional analysis 32 33	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	11-13, eSupplements 2-14				
	·						
35 36 Summary of evidence 37	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13				
38 Limitations 39	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14-16				
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13-16				
42 43 FUNDING							
44 Funding 45	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17				
ય∂ 48 I əb əupidqsıpoildi⊟ əɔnəpA វ⊧ 4 <u>၄</u>	BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l <sup>6</sup> Enseignement Superieur (ABES) . Protected by copyrightsinglanding for uses related to text and data mining. Al training, and similar technologies.						



# **PRISMA 2009 Checklist**

up (2009). Prefere. Pa. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

81 Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de 1<sup>84</sup> Enseignement Superieur (ABES) . 99 Protected by comprised in the ingeneration of the ingeneration

Page 52 of 52

**BMJ Open** 

# **BMJ Open**

# Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomized controlled trials

Journal:	BMJ Open
Manuscript ID	bmjopen-2015-009128.R1
Article Type:	Research
Date Submitted by the Author:	02-Sep-2015
Complete List of Authors:	Tully, Phillip; University of Adelaide, Discipline of Medicine Baumeister, Harald; University of Freiburg, Rehabilitation Psychology and Psychotherapy, Institute of Psychology; University of Freiburg, Medical Psychology and Medical Sociology
<b>Primary Subject Heading</b> :	Mental health
Secondary Subject Heading:	Cardiovascular medicine, Evidence based practice, Mental health
Keywords:	CARDIOLOGY, MENTAL HEALTH, Depression & mood disorders < PSYCHIATRY, Clinical trials < THERAPEUTICS



#### **BMJ Open**

review and meta-analysis of randomized controlled trials Journal for consideration: BMJ Open	
	phillip.tully@adelaide.edu.au
	Harald Baumeister <sup>1,4</sup>
	baumeister@psychologie.uni-freiburg.de
	artment of Rehabilitation Psychology and Psychotherapy, Institute of Psychology versity of Freiburg, Germany
2. Free	emasons Foundation Centre for Men's Health, Discipline of Medicine, School of
	licine, The University of Adelaide, Australia
	ERM, U897-Epidemiology and Biostatistics, Bordeaux, France lical Psychology and Medical Sociology, Faculty of Medicine, University of
Frei	burg, Germany
Correspon	dence:
Harald Bau baumeister	meister @psychologie.uni-freiburg.de
Department	t of Rehabilitation Psychology and Psychotherapy
Institute of	Psychology, University of Freiburg
Engelberge	rstr. 41, D-79085 Freiburg GERMANY
Abstract w	rord count: 293
Manuscrip	t word count: 3,214
Tables: 1	
Figures: 4	t word count: 3,214
Key words	: collaborative care; systematic review; randomized controlled trial; depression;
1	eart disease;

#### ABSTRACT

**Objectives:** To systematically review the efficacy of collaborative care for depression in adults with coronary heart disease (CHD) and depression.

Design: Systematic review and meta-analysis

Data sources: Electronic databases (Cochrane Central Register of Controlled Trials MEDLINE, EMBASE, PsycINFO and CINAHL) were searched until April 2014.

Inclusion criteria: Population, depression comorbid with CHD; intervention, RCT of collaborative care; comparison, either usual care, wait-list control group or no further treatment; and outcome, (primary) major adverse cardiac events (MACE), (secondary) standardized measure of depression, anxiety, quality of life and cost-effectiveness.

Data extraction and analysis: RevMan 5.3 was used to synthesize the data as risk ratios (RR), odds ratios (OR) and standardized mean differences (SMD) with 95% confidence intervals (CI) in random effect models.

**Results:** Six RCTS met the inclusion criteria and were comprised by 655 participants randomized to collaborative care and 629 participants randomized to control group (total 1,284). Collaborative depression care led to a significant reduction in MACE in the short-term (3 trials, RR 0.54; 95% CI 0.31 to 0.95, p = 0.03) that was not sustained in the longer term. Small reductions in depressive symptoms were evident in the short term (6 trials, pooled SMD -0.31; 95% CI -0.43 to -0.19, p < 0.00001) and depression remission was more likely to be achieved with collaborative care (5 trials, OR 1.77; 95% CI 1.28 to 2.44, p = 0.0005).

#### **BMJ Open**

Likewise a significant effect was observed for anxiety symptoms (SMD -.36) and mental quality of life (SMD .24). The timing of intervention was a source of between-group heterogeneity for depression symptoms (between groups p = .04,  $I^2 = 76.5\%$ ).

**Conclusions:** Collaborative depression care did not lead to a sustained reduction in the primary MACE endpoint. Small effects were observed for depression, depression remission, anxiety and mental quality of life.

Review Registration: PROSPERO CRD42014013653

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

data mining, Al training, and similar technologies

Protected by copyright, including for uses related to text

# Strengths

- Systematic review of randomized controlled trials and a priori defined primary and secondary outcomes
- Exhaustive literature search and additional unpublished data provided by 5/6 authors
- GRADE rating of strength of evidence as moderate •

# Limitations

- Heterogeneity observed between studies •
- Few studies performed outside of the USA .
- Insufficient healthcare cost data •

#### **INTRODUCTION**

Depression is widely reported to lead to an adverse coronary heart disease (CHD) prognosis [1 2], poorer quality of life (QOL) [3 4] and high healthcare costs [5]. Despite ongoing efforts to better identify and treat depression [6], prior psychological and pharmacological interventions designed especially for the CHD population have reported markedly lower effect sizes than has been observed among other chronic diseases such as diabetes [7 8]. Moreover, large trials such as the landmark Enhancing Recovery in Coronary Heart Disease (ENRICHD) study [9] did not lead to a significant reduction in major adverse cardiac events (MACE), raising questions about the design [10] and acceptability [11] of depression interventions in the population with CHD.

Collaborative care is emerging as a promising model of healthcare among populations with complex mental health needs [12] and mental disorders comorbid with chronic diseases including diabetes and CHD [13 14]. Collaborative care is defined by a multi-professional approach to patient care delivered by a primary care physician (PCP) and at least one other health professional, involving a structured patient management plan and interventions, scheduled patient follow-ups, and enhanced inter-professional communication between the multi-professional team [13]. Prior systematic reviews have not reported on the efficacy of CHD studies in particular [15 16] although mixed CHD and diabetes samples are commonplace [13]. Several large prospective RCT's of collaborative care versus usual care have been reported recently [17-19] making it feasible to examine the efficacy and early benefits of collaborative care, that might in turn assist in the design of subsequent trials and inform clinical practice. This systematic review extends beyond previous studies by reporting the efficacy of collaborative care for depression in adults with comorbid depression and CHD [20]. BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

#### **METHODS**

#### **Search Strategy**

This review conformed to the PRISMA guidelines [21] and a protocol has been published elsewhere [20]. Electronic databases were searched without language restrictions until April 2014: the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, MEDLINE, EMBASE, PsycINFO and CINAHL. The search string exploded the topics CHD, depression and RCT, as reported previously [20]. Hand searching reference lists of articles selected for full-text supplemented electronic searches. The principal investigators of studies were contacted to ascertain unpublished data and their knowledge of any other collaborative care trials not included in our primary search. Additional data was provided for five trials [17 18 22-24] and no response was received from the TrueBlue study authors [19].

#### **Inclusion Criteria**

Population: RCT studies performed among adults (18 years and older) with comorbid depression and CHD. Depression defined as depression disorder or clinical depression assessed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) by a standardized interview (e.g. Structured Clinical Interview, Composite International Diagnostic Interview), or a validated self-reports or rating scales with specific cut-off points for depression. Mixed samples (e.g. heart failure, arrhythmia, diabetes) were eligible if  $\geq$  50% of the sample have a CHD diagnosis. Intervention: collaborative care intervention defined as a coordinated model of care involving multidisciplinary healthcare providers, including: (a) at least one health professional (e.g. nurse, psychiatrist, psychologist) in addition to the PCP; (b) a structured patient management

#### **BMJ Open**

plan that delivers either pharmacological or non-pharmacological depression intervention; (c) scheduled patient follow-up; (d) enhanced inter-professional communication between the multiprofessional team. Collaborative care may include usual CHD care or blended depression-CHD care.

Comparison: control group being either (enhanced) usual care, wait-list control group, or no further treatment for comorbid depression-CHD.

Outcomes: Primary; all-cause and CHD-related mortality as well as MACE (e.g. subsequent myocardial infarction, coronary revascularization procedure, incident heart failure, stroke). Secondary; secondary outcomes include depression, anxiety and quality of life (measured either dimensionally or categorically) following the intervention assessed by validated self-report questionnaires or standardized interview. In addition, we considered economic evaluations of health care costs or resource utilization including cost-effectiveness (incremental cost-effectiveness ratio) and cost-utility (quality-adjusted life years).

#### Study Selection Process, Risk of Bias and Assessment

Two reviewers (PJT, HB) independently screened abstracts and articles for eligibility. In the case of title/abstract disagreements, the study was subjected to full-text review and disagreements were resolved by discussion. Two reviewers (PJT, HB) independently assessed included studies using the Cochrane Collaboration's tool for assessing risk of bias [25]. The tool covers sequence generation, allocation concealment, selective outcome reporting and other sources of bias. Adjudication of the strength of evidence for each endpoint was made according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria with GRADE Profiler 3.6.1 [26].

#### Synthesis of Data and Summary Measures

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text and

#### BMJ Open

Standardized mean differences (SMD) for continuous variables, risk ratios (RR) for MACE and odds ratios (OR) for dichotomous endpoints are reported with 95% CI. Data were pooled together with random effect models using the inverse-variance method [25 27]. To evaluate the presence of publication bias, the funnel plot was inspected. All analyses were performed with RevMan Version 5.3.

#### RESULTS

The search yielded 1,755 citations from which 46 articles were reviewed in detail, 16 papers were retained which reported on 6 RCTs (Figure 1). Five collaborative care trials performed with diabetes and CHD or mixed chronic disease populations were excluded as they did not meet the threshold of more than 50% CHD patients [13 28-31]. Two trials were close to meeting the definition of collaborative care for depression comorbid with CHD but were excluded. The IDACC [32] study was excluded as the intervention did not initiate pharmacological or non-pharmacological depression treatment and did not involve structured follow-up of participants to augment treatment if necessary. The UPBEAT-UK study [33] was excluded as the intervention was a case-management intervention and did not incorporate other healthcare professionals such as the PCP.

The 6 RCTs that met the inclusion criteria comprised a total of 1,284 patients with comorbid depression and CHD: 655 participants randomized to collaborative care and 629 participants randomized to a control group. A description of the included trials' is shown in Table 1. The median proportion of participants with CHD in the trials was 78.9% suggesting high representative sampling of the chronic disease understudy. The median sample size was 179 participants per study with a median of 47.6% female participants. Four trials recruited participants from multiple sites [11 34-36] and two trials were performed at a single-center

#### BMJ Open

[17 37]. Five trials were from the United States of America [17 18 22-24] and one trial was performed in Australia [19]. The comparison group was usual care or enhanced usual care in five studies consisting of informing participants' PCP [17 18 22-24] and one trial used a wait-list control group [36].

Depression screening questionnaires varied only minimally. Depression was assessed with the Patient Health Questionnaire (PHQ) to determine study eligibility in 4 trials [17 19 23 24]. Specifically three trials used a two-step screening approach with the PHQ-2 and a PHQ-9 for participants with an initial positive depression response on the PHQ-2 [17 35 37]. These trials used a moderate depression threshold consisting of PHQ-9 total scores  $\geq$  10 [17 35 37]. The TrueBlue study [36] included patients with mild depression symptoms consisting of PHQ-9 scores  $\geq$  5. In the COPES and CODIACS trials the Beck Depression Inventory (BDI) was used for screening and trial eligibility [11 34]. The clinical cutoff was set at  $\geq$  10 on at least two different screening occasion's in COPES [11]. In CODIACS [34] the clinical cutoff was set at BDI  $\geq$  10 on at least two different screening occasion's or BDI  $\geq$  15 on 1 occasion. Five of the trials utilizing either the PHQ-9 [17 36 37] or Beck Depression Inventory [11 34] to determine trial eligibility also used the same measure for depression symptom response at the conclusion of the trial. The Bypassing The Blues trial employed the Hamilton Rating Scale for Depression [24] for depression symptom clinical response.

Collaborative care was managed by an allied health team in two trials [11 34], by nurses in two studies [35 36] and by social workers in two studies [17 37]. The collaborative care intervention duration ranged from 3 to 12 months and the median duration was 6 months. The psychotherapy component of the collaborative care package consisted of problem-solving therapy in two studies [11 34], telephone-delivered manualized CBT in one study [37], referral to community mental health services in two studies [35 36], and was mixed in another

#### **BMJ Open**

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

study [17]. The pharmacological component of the trials varied. In Bypassing The Blues [35] depression pharmacotherapy consisted of citalopram, serotonin norepinephrine reuptake inhibitor or bupropion. In CODIACS [34] depression pharmacotherapy consisted of sertraline, citalopram, or bupropion. In COPES [11] pharmacotherapy consisted of sertraline, escitalopram, venlafaxine, bupropion and mirtazipine. In MOSAIC [37] depression pharmacotherapy consisted of selective serotonin reuptake inhibitor (SSRI, most commonly citalopram), serotonin norepinephrine reuptake inhibitor, bupropion, mirtazapine and anxiety treatment with SSRI or benzodiazepine. In SUCCEED [17] depression pharmacotherapy consisted of SSRI. No specific depression pharmacotherapy regimen was reported in TrueBlue [36].

#### **Risk of Bias**

Risk of bias varied in the included primary trials (eSupplement 1). Missing trial characteristics were common despite all studies having published a trial protocol. In four trials the allocation concealment was unclear. Blinding to subjective endpoints was rated as high in all studies. Selective reporting was noted in three studies because of discrepancies in the study endpoints reported in the protocol by comparison to the primary trial results.

#### **Primary Outcome: Major Adverse Cardiac Events**

Three trials reported MACE [18 24 38] and pooling all data irrespective of follow-up showed that collaborative care did not reduce MACE (RR = 0.87; 95% CI 0.53 to 1.42, p =.20,  $I^2 = 39\%$ ). Collaborative care was associated with significant reduction in MACE during the short to medium term (RR = 0.54; 95% CI 0.31 to 0.95, p = 0.03) that was not sustained in the long-term (> 12 months follow-up) where only the COPES trial [39] reported MACE (RR

#### **BMJ Open**

1.04; 95% CI 0.51 to 2.14, p = 0.91) (Fig 2). There was no association with mortality (5 trials, RR 1.38; 95% CI 0.53 to 3.58, p = 0.51).

#### **Secondary Outcomes**

Depression Symptoms and Remission

All 6 trials reported change in self-reported depression symptoms by six months postintervention. Collaborative care was associated with a significant reduction in depressive symptoms (pooled SMD –0.31; 95% CI –0.43 to –0.19, p <.00001:  $I^2 = 13\%$ ) (Fig 3). There was no depression symptom data available in the medium or long term. Four trials reported depression remission or clinically significant depression response and additional data was provided by the MOSAIC trial [23]. Collaborative care was significantly associated with depression remission (OR = 1.77; 95% CI 1.28 to 2.44, p = .0005:  $I^2 = 23\%$ ) (Fig 4). In the medium term only the COPES trial [39] reported depression response based on the BDI  $\leq 10$ (OR 2.26; 95% CI 1.14 to 4.46, p = .02). As the COPES trial [39] reported similar depression remission results in the short to medium term pooling all depression remission data in the 5 trials, irrespective of timeframe, indicated similar results.

#### **Other Secondary Outcomes**

The forest plots for each of the secondary endpoints are reported in eSupplements 2 through 5. Four trials reported anxiety symptom change. It was found that collaborative care led to a small but significant reduction in anxiety symptoms in the short term (SMD -0.36; 95% CI -0.54 to -0.17, p = 0.0001:  $I^2 = 25\%$ ). Collaborative care was also associated with a significant improvement in mental quality of life in the short term across five trials (SMD 0.23; 95% CI 0.08 to 0.38, p = 0.003:  $I^2 = 27\%$ ), while effects for physical QOL were non-significant (SMD 0.11; 95% CI -0.03 to 0.25, p = 0.12:  $I^2 = 13\%$ ). In terms of cost-effectiveness, there was no significant benefit afforded by collaborative care based on two

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

trials in the short term (SMD -0.09; 95% CI -0.32 to 0.13, p = 0.42:  $I^2 = 0\%$ ). Medium term results were reported by Bypassing The Blues [40] which did not indicate significantly lower costs with collaborative care (SMD 0.07; 95% CI -0.22 to 0.35, p = 0.65).

#### **Ancillary Analyses**

We performed ancillary analysis with each constituent of the MACE endpoint encompassing acute coronary syndrome hospitalizations, coronary revascularization, heart failure and stroke. There was no significant effect for collaborative care to reduce any of these more specific cardiovascular endpoints (eSupplements 6 through 9). Also, as five trials differentiated between MACE and cardiac-cause hospital readmissions we performed an analysis according to the latter outcome which occurs more frequently. Analysis of 5 trials showed no significant reduction in cardiac-cause hospital readmissions (RR = 0.89; 95% CI 0.66 - 1.19, p = 0.43: I<sup>2</sup> = 35%) (eSupplement 10).

### **Sensitivity Analyses**

For depression change, a sensitivity analysis was performed excluding the trials comprised by diabetes patients without CHD [19] and non-depressed CHD patients with anxiety [23]. The sensitivity analysis revealed a small increase in the effect size (pooled SMD -.39; 95% CI -.53 to -.25, p <.00001: I<sup>2</sup> = 0%). We also evaluated the trials comprised by patients with only CHD (excluding other cardiac disorders) and assessed depression response. The trials were associated with depression remission (OR = 1.94; 95% CI 1.40 - 2.70, p = <0.0001:  $I^2 = 39\%$ ) and depression symptom reduction (pooled SMD -0.43; 95% CI -0.59 to -0.27, p <.00001: I<sup>2</sup> = 0%).

The timing of depression onset [41] and intervention [11] after a cardiac hospitalization has been raised by several scholars as an important methodological

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ Open**

consideration. Thus we stratified studies as providing collaborative care immediately upon screening or as an in-patient [17 36 37] versus those which considered depression chronicity with a secondary screener at a later stage and as an outpatient [11 34 35]. It was found that timing of depression intervention was a source of between-group heterogeneity for depression severity in six trials (between groups p = .04,  $I^2 = 76.5\%$ ) (eSupplement 11), but not for depression remission (between groups p = .50,  $I^2 = 0\%$  (eSupplement 12).

When analyzing the effect of collaborative care in relation to components of depression treatment, as described in our protocol [20], it was found that collaborative care was not associated with higher prescription rate of antidepressant medication (6 trials, OR = 1.38; 95% CI 0.91 to 2.10, p = .13, I<sup>2</sup> = 62%). There was no increase in the initiation of psychological therapy with collaborative care (6 trials, OR 2.01; 95% CI 0.85 to 4.76, p = .11, I<sup>2</sup> = 84%) (eSupplement 13 and 14).

#### **Publication Bias and GRADE Strength of Recommendations**

Testing for publication bias was inappropriate as fewer than 10 RCTs were eligible. All of the primary and secondary outcomes were graded as moderate strength according to the GRADE [26] criteria (eSupplement 15).

#### DISCUSSION

This systematic review adds to the extant literature by reporting the efficacy and healthcare costs of collaborative care interventions in comorbid depression and CHD populations. It was found that collaborative care was associated with a significant reduction in MACE in the short term (< 6 months) that was not sustained in the longer term. The absence of significant reduction in MACE in the longer term is comparable to other findings with

BMJ Open: first published as 10.1136/bmjopen-2015-009128 on 21 December 2015. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) .

data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text and

#### **BMJ Open**

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

pharmacological or psychological interventions [8 42]. The results pertaining to the secondary depression endpoints indicated a small albeit significant reduction in depression symptoms with collaborative care, and depression remission was also more likely in the short term. In addition, collaborative care was associated with a significant reduction in anxiety symptoms and an improvement in mental OOL. The findings did not suggest a significant benefit for physical QOL or healthcare costs. Taken together the findings generally support previous systematic reviews regarding more specific depression treatments such as antidepressants or psychotherapy in the population with CHD [8 42].

The significant reduction in MACE in the short term contrasts a prior Cochrane review [8] and other systematic reviews reporting on medical outcomes [43 44]. However the generalization of our findings are limited as only three trials reported the primary MACE endpoint in the short term. Thus it is likely that there were simply too few MACE reported resulting in low statistical power. This is further exemplified by comparing the cumulative sample in our analyses to the ENRICHD study [9] which randomized 2,481 myocardial infarction patients to cognitive behavioral therapy supplemented with selective serotonin reuptake inhibitors versus usual care. At 29-month follow-up in the ENRICHD trial there was no difference in event free survival from death or recurrent myocardial infarction (75.8% intervention vs. 75.9% usual care) [9]. The longer-term MACE findings of our review align with the general consensus that depression treatment does not lead to a clinically meaningful impact upon cardiovascular events in CHD patients [45-47]. With regards to depression remission, short term results with collaborative care were promising indicating a higher remission rate with collaborative care. However only the COPES trial [39] reported medium term follow-up data. With regards to secondary endpoints of anxiety and mental QOL the results here appear comparable to other systematic reviews on psychological interventions [8].

#### **BMJ Open**

The limitations of the primary studies are that the predominant collaborative care research has been performed in the United States of America [17 18 22-24] with only one Australian study included here [19]. Other collaborative care trials that did not meet our CHD threshold have been performed in the United Kingdom [28] and The Netherlands [48]. Further trials with CHD populations may assist in clarifying the extent to which collaborative care can be readily applied in other healthcare settings outside the United States of America. As a consequence of low uptake of collaborative care RCTs outside the USA, the total number of RCTs retained for our meta-analysis was low. Moreover, the infrequent reporting of MACE and mortality data in the original studies limited our analyses to 3 trials. Another limitation was that risk of bias assessment showed that some studies were characterized by methodological limitations, especially a lack of blinding regarding intervention staff and participants (which is not possible in collaborative care interventions when compared to usual care) and blinding of depression assessment (i.e. only self-report instruments used).

Diversity in the design of collaborative care and control group may have also led to heterogeneity between the studies. In favour of a more comprehensive overview of the topic we included studies with diabetes [19] and anxiety [23]. As shown in sensitivity analyses, this might have underestimated the effect sizes when compared to cardiac-depression populations only. Indeed, evidence for collaborative care appears to be more firmly established in the population with diabetes [43] highlighting discrepancies between depression intervention efficacy in CHD [7 8]. Given that collaborative care interventions consist of scheduled follow-up it cannot be ruled out that depression efficacy was partly attributable to the attention given to participants in the treatment condition. Further RCTs using attention control groups might also explicate whether treatment effects are partly attributable to time spent with patients.

#### BMJ Open

In conclusion, collaborative depression care in the CHD population did not lead to a sustained reduction in MACE. Small reductions in depressive symptoms were evident for collaborative care and intervention participants were more likely to achieve depression remission. Small effect sizes for anxiety symptom reduction and improvement in mental QOL were evident with collaborative care. However it remains to be shown that collaborative depression care can lead to sustained reductions in cardiovascular events and a moderate depression response in the longer term. Scant RCT data exists outside of the USA and the cost-effectiveness has not been established at this time.

#### **BMJ Open**

Contributor statement: Study design (PJT, HB), article selection (PJT, HB), analyses (PJT, HB), writing manuscript (PJT, HB)

Competing interests: none to declare

Funding: This work was supported by the National Health and Medical Research Council of Australia (#1053578) and the article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding program Open Access Publishing.

Data sharing statement: None

Acknowledgements: We thank the collaborative care trial authors for generously providing additional data required in this review: Prof. Bea Belnap, Prof. Karina Davidson, Prof. Jeff Huffman and Prof. Bruce Rollman.

Protected by copyright, including for uses related

to text

ta mining, Al training, and similar technologies

**Figure Captions.** 

Fig 1. Flow chart of article selection

Fig 2. Forest plot showing the risk ratio for MACE post intervention in collaborative care studies versus usual care or waiting list control (short and medium term)

CI, confidence interval; MACE, major adverse cardiac event; IV, inverse variance;

Fig 3. Forest plot showing depressive symptoms in collaborative care studies versus usual care or waiting list control (short term)

CI, confidence interval; IV, inverse variance; SD, standard deviation

Fig 4. Forest plot showing depression remission in collaborative care studies versus usual care or waiting list control (short and medium term)

*CI*, confidence interval; *IV*, inverse variance;

	REFERENCES
1. E	Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in
	patients with coronary heart disease: a meta-analysis. Psychosom Med
	2004;66(6):802-13 doi: 10.1097/01.psy.0000146332.53619.b2[published Online Fir
	Epub Date]l.
2. I	ichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor
	prognosis among patients with acute coronary syndrome: systematic review and
	recommendations: a scientific statement from the American Heart Association.
	Circulation 2014;129(12):1350-69 doi: 10.1161/cir.000000000000019[published
	Online First: Epub Date]l.
3. S	amartzis L, Dimopoulos S, Tziongourou M, Nanas S. Effect of psychosocial interventio
	on quality of life in patients with chronic heart failure: A meta-analysis of randomiz
	controlled trials. Journal of Cardiac Failure 2013;19(2):125-34
4. E	Baumeister H, Hutter N, Bengel J, Härter M. Quality of life in somatically ill persons wit
	comorbid mental disorders: a systematic review and meta-analysis. Psychother
	Psychosom 2011;80:275-86 doi: 10.1159/000323404.[published Online First: Epub
	Date]l.
5. F	Baumeister H, Haschke A, Munzinger M, Hutter N, Tully PJ. Inpatient and outpatient co
	in patients with coronary artery disease and mental disorders: A systematic review.
	BioPsychoSocial medicine 2015;9(11) doi: doi:10.1186/s13030-015-0039-z[publish
	Online First: Epub Date]l.
б. Т	Fully PJ, Higgins R. Depression screening, assessment and treatment for patients with
	coronary heart disease: a review for psychologists. Australian Psychologist
	2014; <b>49</b> (6):337–44
7. F	Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for
	depression in patients with diabetes mellitus- a systematic Cochrane review. Diabet
	Med 2014 doi: 10.1111/dme.12452[published Online First: Epub Date]l.
8. F	Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for
	depression in patients with coronary artery disease. Coch Data Syst Rev
	2011;9:CD008012 doi: 10.1002/14651858.CD008012.pub3[published Online First:
	Epub Date]l.
9. F	Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceiv

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

#### **BMJ Open**

in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. Journal of the American Medical Association 2003;289(23):3106-16

- 10. Linden W. How many meta-analyses does it take to settle a question? Psychosomatic Medicine 2013;75(4):332-4 doi: 10.1097/PSY.0b013e318295e046[published Online First: Epub Date]|.
- 11. Burg MM, Lesperance F, Reickmann N, Clemow L, Skotzko C, Davidson KW. Treating persistent depressive symptoms in post-ACS patients: The project COPES Phase-1 randomized controlled trial Contemp Clin Trials 2008;29(2):231-40
- 12. Archer J, Bower P, Gilbody S, et al. Collaborative care for depression and anxiety problems. Cochrane Database of Systematic Reviews 2012;10:CD006525 doi: 10.1002/14651858.CD006525.pub2[published Online First: Epub Date]|.
- 13. Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. New England Journal of Medicine 2010;363(27):2611-20 doi: 10.1056/NEJMoa1003955[published Online First: Epub Date]l.
- 14. Huffman JC, Niazi SK, Rundell JR, Sharpe M, Katon WJ. Essential articles on collaborative care models for the treatment of psychiatric disorders in medical settings: a publication by the Academy of Psychosomatic Medicine Research and Evidence-Based Practice Committee. Psychosomatics 2014;55:109-22 doi: 10.1016/j.psym.2013.09.002[published Online First: Epub Date]l.
- 15. Woltmann E, Grogan-Kaylor A, Perron B, Georges H, Kilbourne AM, Bauer MS. Comparative effectiveness of collaborative chronic care models for mental health conditions across primary, specialty, and behavioral health care settings: systematic review and meta-analysis. Am J Psychiatry 2012;169(8):790-804 doi: 10.1176/appi.ajp.2012.11111616[published Online First: Epub Date].
- 16. Watson LC, Amick HR, Gaynes BN, et al. Practice-based interventions addressing concomitant depression and chronic medical conditions in the primary care setting: a systematic review and meta-analysis. Journal of primary care & community health 2013;4(4):294-306 doi: 10.1177/2150131913484040[published Online First: Epub Date]|.
- 17. Huffman JC, Mastromauro CA, Sowden GL, Wittmann C, Rodman R, Januzzi JL. A collaborative care depression management program for cardiac inpatients: depression characteristics and in-hospital outcomes. Psychosomatics 2011;52(1):26-33 doi: 10.1016/j.psym.2010.11.021[published Online First: Epub Date]|.

#### **BMJ Open**

18. D	avidson KW, Bigger JT, Burg MM, et al. Centralized, stepped, patient preference-based
	treatment for patients with post-acute coronary syndrome depression: CODIACS
	vanguard randomized controlled trial. JAMA Internal Medicine 2013;173(11):997-
	1004 doi: 10.1001/jamainternmed.2013.915[published Online First: Epub Date]l.
19. M	organ MA, Coates MJ, Dunbar JA, Reddy P, Schlicht K, Fuller J. The TrueBlue model
	of collaborative care using practice nurses as case managers for depression alongside
	diabetes or heart disease: a randomised trial. BMJ open 2013;3(1) doi:
	10.1136/bmjopen-2012-002171[published Online First: Epub Date]l.
20. Ti	ally PJ, Baumeister H. Collaborative care for the treatment of comorbid depression and
	coronary heart disease: a systematic review and meta-analysis protocol Systematic
	Reviews 2014; <b>3</b> :127
21. Li	berati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic
	reviews and meta-analyses of studies that evaluate healthcare interventions:
	explanation and elaboration. BMJ 2009; <b>339</b> :b2700
22. D	avidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients
	with acute coronary syndrome and persistent depressive symptoms: coronary
	psychosocial evaluation studies randomized controlled trial. Archives of Internal
	Medicine 2010; <b>170</b> (7):600-8 doi: 10.1001/archinternmed.2010.29[published Online
	First: Epub Date]l.
23. H	uffman JC, Mastromauro CA, Beach SR, et al. Collaborative care for depression and
	anxiety disorders in patients with recent cardiac events: The Management of Sadness
	and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med
	2014; <b>174</b> (6):927-36 doi: 10.1001/jamainternmed.2014.739[published Online First:
	Epub Date]l.
24. R	ollman BL, Belnap BH, LeMenager MS, et al. Telephone-delivered collaborative care
	for treating post-CABG depression: a randomized controlled trial. Journal of the
	American Medical Association 2009; <b>302</b> (19):2095-103 doi:
	10.1001/jama.2009.1670[published Online First: Epub Date]l.
25. H	iggins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions.
	Chichester, West Sussex, UK: John Wiley & Sons Ltd., 2008.
26. Tl	he GRADE Working Group. GRADE handbook for grading quality of evidence and
	strength of recommendations. Updated October 2013 In: Schünemann H, Brożek J,
	Guyatt G, Oxman AD, eds., 2013.

#### **BMJ Open**

27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21(11):1539-58 doi: 10.1002/sim.1186[published Online First: Epub Date]l.

- 28. Coventry P, Lovell K, Dickens C, et al. Integrated primary care for patients with mental and physical multimorbidity: cluster randomised controlled trial of collaborative care for patients with depression comorbid with diabetes or cardiovascular disease. BMJ 2015;**350**:h638 doi: 10.1136/bmj.h638[published Online First: Epub Date]l.
- 29. Bogner HR, de Vries HF. Integration of Depression and Hypertension Treatment: A Pilot, Randomized Controlled Trial. The Annals of Family Medicine 2008;6(4):295-301 doi: 10.1370/afm.843[published Online First: Epub Date]l.
- 30. Stewart JC, Perkins AJ, Callahan CM. Effect of Collaborative Care for Depression on Risk of Cardiovascular Events: Data From the IMPACT Randomized Controlled Trial. Psychosomatic Medicine 2014;76(1):29-37 doi: 10.1097/psy.00000000000022[published Online First: Epub Date]l.
- 31. Vera M, Perez-Pedrogo C, Huertas SE, et al. Collaborative Care for Depressed Patients With Chronic Medical Conditions: A Randomized Trial in Puerto Rico. Psychiatric services (Washington, D.C.) 2010;61(2):144-50 doi: 10.1176/appi.ps.61.2.144[published Online First: Epub Date]l.
- 32. Cheok F, Schrader G, Banham D, Marker J, Hordacre AL. Identification, course, and treatment of depression after admission for a cardiac condition: rationale and patient characteristics for the Identifying Depression As a Comorbid Condition (IDACC) project. American Heart Journal 2003;146(6):978-84
- 33. Tylee A, Haddad M, Barley E, et al. A pilot randomised controlled trial of personalised care for depressed patients with symptomatic coronary heart disease in South London general practices: the UPBEAT-UK RCT protocol and recruitment. BMC Psychiatry 2012;12:58 doi: <u>http://dx.doi.org/10.1186/1471-244X-12-58[published</u> Online First: Epub Date]l.
- 34. Whang W, Burg MM, Carney RM, et al. Design and baseline data from the vanguard of the Comparison of Depression Interventions after Acute Coronary Syndrome (CODIACS) randomized controlled trial. Contemp Clin Trials 2012;33(5):1003-10 doi: 10.1016/j.cct.2012.05.005[published Online First: Epub Date]l.
- 35. Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Schulberg HC, Reynolds CF,
  3rd. The Bypassing the Blues treatment protocol: stepped collaborative care for
  treating post-CABG depression. Psychosom Med 2009;71(2):217-30 doi:
  PSY.0b013e3181970c1c [pii]

#### **BMJ Open**

10.1097/PSY.0b013e3181970c1c [doi][published Online First: Epub Date]l.
36. Morgan M, Dunbar JA, Reddy P, Coates M, Leahy R. The TrueBlue study: Is practice
nurse-led collaborative care effective in the management of depression for patients
with heart disease or diabetes? BMC Family Practice 2009;10(1):46
37. Huffman JC, Beach SR, Suarez L, et al. Design and baseline data from the Management
of Sadness and Anxiety in Cardiology (MOSAIC) randomized controlled trial.
Contemp Clin Trials 2013 doi: 10.1016/j.cct.2013.09.012[published Online First:
Epub Date]l.
38. Ladapo JA, Shaffer JA, Fang Y, Ye S, Davidson KW. Cost-effectiveness of enhanced
depression care after acute coronary syndrome: Results from the coronary
psychosocial evaluation studies randomized controlled trial. Archives of Internal
Medicine 2012; <b>172</b> (21):1682-84 doi: 10.1001/archinternmed.2012.4448[published
Online First: Epub Date]l.
39. Ye S, Shaffer JA, Rieckmann N, et al. Long-term outcomes of enhanced depression
treatment in patients with acute coronary syndromes. Am J Med 2014;127(10):1012-6
doi: 10.1016/j.amjmed.2014.05.004[published Online First: Epub Date]l.
40. Donohue JM, Belnap BH, Men A, et al. Twelve-month cost-effectiveness of telephone-
delivered collaborative care for treating depression following CABG surgery: a
randomized controlled trial. General Hospital Psychiatry 2014; <b>36</b> (5):453-59
41. Parker GB, Hilton TM, Walsh WF, et al. Timing is everything: the onset of depression
and acute coronary syndrome outcome. Biol Psychiatry 2008;64(8):660-6
42. Whalley B, Thompson DR, Taylor RS. Psychological interventions for coronary heart
disease: Cochrane systematic review and meta-analysis. Int J Behav Med
2014; <b>21</b> (1):109-21. doi: 10.1007/s12529-012-9282-x[published Online First: Epub
Date]l.
43. Huang Y, Wei X, Wu T, Chen R, Guo A. Collaborative care for patients with depression
and diabetes mellitus: a systematic review and meta-analysis. BMC Psychiatry
2013;13(1):1-11 doi: 10.1186/1471-244X-13-260[published Online First: Epub Date]l.
44. Ekers D, Murphy R, Archer J, Ebenezer C, Kemp D, Gilbody S. Nurse-delivered
collaborative care for depression and long-term physical conditions: A systematic
review and meta-analysis. Journal of Affective Disorders 2013;149(1-3):14-22 doi:
http://dx.doi.org/10.1016/j.jad.2013.02.032[published Online First: Epub Date]l.
45. Dickens C, Cherrington A, Adeyemi I, et al. Characteristics of psychological interventions
that improve depression in people with coronary heart disease: a systematic review
23

#### **BMJ Open**

and meta-regression. Psychosom Med 2013;75(2):211-21 doi:

10.1097/PSY.0b013e31827ac009.[published Online First: Epub Date]l.

- 46. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. American Journal of Cardiology 2011;107(7):972-9 doi: 10.1016/j.amjcard.2010.11.017.[published Online First: Epub Date]l.
- 47. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. Journal of the American College of Cardiology 2006;48(8):1527-37 doi: <u>http://dx.doi.org/10.1016/j.jacc.2006.06.055[published</u> Online First: Epub Date]l.
- 48. van Dijk SE, Pols AD, Adriaanse MC, et al. Cost-effectiveness of a stepped-care intervention to prevent major depression in patients with type 2 diabetes mellitus and/or coronary heart disease and subthreshold depression: design of a cluster-randomized controlled trial. BMC Psychiatry 2013;13:128 doi: <a href="http://dx.doi.org/10.1186/1471-244X-13-128[published">http://dx.doi.org/10.1186/1471-244X-13-128[published</a> Online First: Epub Date]l.
- 49. Kronish IM, Rieckmann N, Burg MM, Edmondson D, Schwartz JE, Davidson KW. The effect of enhanced depression care on adherence to risk-reducing behaviors after acute coronary syndromes: findings from the COPES trial. Am Heart J 2012;164(4):524-9 doi: 10.1016/j.ahj.2012.07.024[published Online First: Epub Date]l.
- 50. Beach SR, Januzzi JL, Mastromauro CA, et al. Patient health questionnaire-9 score and adverse cardiac outcomes in patients hospitalized for acute cardiac disease. Journal of Psychosomatic Research 2013;75:409-13 doi:

http://dx.doi.org/10.1016/j.jpsychores.2013.08.001[published Online First: Epub Date]l.

### Table 1. Characteristics of included collaborative care studies in the treatment of


#### comorbid depression and coronary heart disease

Study, Country	Design and Intervention Length	CHD population (% CHD in total sample)	Sample Size of CC vs. UC (% females in total sample)	Depression Assessment	Collaborative Care Intervention	Control Group
Bypassing The Blues, Rollman et al. 2009, USA [24 35 40]	Single-blind effectiveness RCT, 8 months	CABG (100%)	150 CC vs. 152 UC (41.4)	PHQ-2 positive screen as an inpatient and PHQ-9 score ≥ 10 2 weeks post-CABG, PRIME-MD for mood disorders	Structured telephone f/up, patient preferences for depression care, psychoeducation, bibliotherapy, promoting adherence, and initiation or adjustment of antidepressant pharmacotherapy provided by PCP (citalopram, SNRI or bupropion); referral to a community MHS; a combination of the above; "watchful-waiting"	Usual care, given brochure on depression an- heart disease, PCP informed of depression status
CODIACS, Davidson et al. USA [ <b>18 34</b> ]	Single-blind effectiveness RCT, 6 months	UA, MI (100%)	73 CC vs. 77 UC (42.0)	BDI-I score $\geq$ 10 on 2 screening occasions or $\geq$ 15 on 1 occasion 2 to 6 months after hospitalization	Initial patient preference for problem-solving therapy and/or pharmacotherapy (sertraline, citalopram, buproprion), or neither, then a stepped-care approach every 6-8 weeks, structured f/up initially every week with PST or 1-2 and 3 - 5 weeks to titrate doses with pharmacotherapy, study team included a site physician and fed back information to PCP	Usual care, locally administered, ad libitum depression care, PCP informed of depression status
COPES, Davidson et al. [11 22 38 39 49]	Single-blind effectiveness RCT, 6 months	UA, MI (100%)	80 CC vs. 77 UC (53.5)	BDI-I score $\geq$ 10 on 2 screening occasions 1 week and 3 months after hospitalization	Initial patient preference for problem-solving therapy and/or pharmacotherapy (sertraline, escitalopram, venlafaxine, bupropion, mirtazapine), then a stepped-care approach, repeated	Usual care, locally administered, ad libitum depression care, PCP informed of depression status


			BMJ Op	en		Pa	ge 26 o
					assessments and augmentation if required at 8 week intervals, structured f/up initially every week with PST or 1-2 and $3 - 5$ weeks to titrate doses with pharmacotherapy, study team included a site physician and fed back information to PCP		Protected by
MOSAIC, Huff nan et al., USA [23 37]	Single-blind effectiveness RCT, 6 months	UA, MI, HF, arrhythmia (51%)	92 CC vs. 91 EUC (53.0)	Two-step screening process; PHQ-2, GAD-2 and item about panic attacks as an inpatient and PRIME-MD for depression, GAD and PD	Social worker and psychiatrist developed individualized treatment recommendations; patient preference for pharmacotherapy (SSRI most commonly citalopram, SNRI, bupropion, mirtazapine and anxiety treatment with SSRI or benzodiazepine) or CBT (min. six session CBT when allocated); stepped- care; PCP informed of patient preference; structured telephone call and f/up to monitor symptoms, promote adherence and engagement;	Enhanced usual care, PCP informed of psychiatric status at baseline and subsequent screening	Protected by copyright, including for uses related to text and data mining, Al
SUCCEED Huffman et al 2011, USA [17 50]	Single-blind effectiveness RCT, 3 months	UA, MI, HF, arrhythmia (52.6%)	90 CC vs. 85 UC (48.6)	Two-step screening process; PHQ-2 positive screen and PHQ-9 score ≥ 10 as an inpatient	Social worker and psychiatrist individualized depression treatment recommendations based on history and patient preference (SSRI or psychotherapy); study team provided the PCP or cardiologist with treatment recommendations; verbal and written recommendations to the inpatient treatment team; depression education for pleasant activities scheduling; monitored for	Usual care, PCP informed of depression status	iníng, Al training, and similar technologies.
						26	

					adequate depression response;	
TrueBlue, Morgan et al., AUS [19 36]	Cluster randomized RCT, 12 months	CHD and diabetes (57.8)	170 CC vs. 147 WLC (46.7)	PHQ-9 score ≥ 5 as a primary care patient	Scheduled visits to PN and PCP every 3 months over 12- months; referrals to MHS; development and recording of patient goals;	Usual care PN monito depression screening a schedulec intervals

BDI-I; Beck Depression Inventory-I; CABG, coronary artery bypass graft; CC, collaborative care; CHD, coronary heart disease; COPES, Coronary Psychosocial Evaluation Studies; CODIACS, Centralized, Stepped, Patient Preference–Based Treatment for Patients With Post–Acute Coronary Syndrome Depression; GAD, generalized anxiety disorder; HF, heart failure; MHS, mental health services; MI, myocardial infarction; MOSAIC, Management of Sadness and Anxiety in Cardiology; PCP, primary care physician; PD, panic disorder; PHQ, Patient Health Questionnaire; PN, practice nurse; PRIME-MD, Primary Care Evaluation of Mental Disorders; PST, problem-solving therapy; RCT, randomized controlled trial; SSRI, selectoive serotonin reuptake inhibitors; SNRI, serotonin norepinephrine reuptake inhibitor; SUCCEED, Screening Utilization and e Effectiv Collaborative Care for More Effective and Efficient Treatment of Depression; UA, unstable angina; WLC, waitlist control:



#### **BMJ Open**



**BMJ Open** 

1 2	
2 3 4 5	
6	
7 8 9	
10	
11 12 13	
14 15	
16 17	
18 19 20	
20 21 22	
23 24	
25 26	
27 28 20	
30 31	
32 33	
34 35 26	
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	
39 40	
41 42	
43 44 45	
46 47	
48 49	
50 51 52	
52 53 54	
55 56	
57 58	
59 60	

Study or Subgroup	Collaborative Care Mean SD To		rotal Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
3.2.1 Short Term Bypass The Blues 2009 CODIACS 2013 COPES 2010 MOSAIC 2014 SUCCEED 2011 TrueBlue 2013 Subtotal (95% CI) Heterogeneik; Tau <sup>a</sup> = 0.00 Test for overall effect. Z = 5	-7.6 7.3485 1 -10.1 8.1434 -5.7 8.5378 -8.06 6.9364 -8.67 7.1618 -3.6 10.245 1 6 ; Chi² = 5.73, df = 5 (P	50 -4.5 7.3973 73 -6.6 8.3711 80 -1.9 8.3711 91 -6.01 6.9364 90 -6.9 6.027 64 -2.6 10.8747 48	152 22.6% 77 12.3% 77 12.7% 92 14.8% 85 14.2% 146 23.4% 629 100.0%	-0.42 [0.65,-0.19] -0.42 [0.76,-0.10] -0.45 [0.76,-0.13] -0.29 [0.59,-0.00] -0.27 [0.56,0.03] -0.09 [-0.32,0.13] -0.31 [-0.43,-0.19]	-1 -0.5 0 0.5 1 Favours Collab. Care Favours Control
		240x67	'mm (96	5 x 96 DPI)	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

~	Collaborative (		Contr			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	weight	IV, Random, 95% CI	IV, Random, 95% Cl
3.1.1 Short term							
Bypass The Blues 2009	75	150	45	152	30.2%	2.38 [1.48, 3.82]	
CODIACS 2013	38	73	37	77	19.5%	1.17 [0.62, 2.23]	
COPES 2010	34	80	19	77	17.7%	2.26 [1.14, 4.46]	
MOSAIC 2014	19	55	9	47	10.8%	2.23 [0.89, 5.56]	
SUCCEED 2011	44	90	37	85	21.8%	1.24 [0.68, 2.25]	
Subtotal (95% CI)		448		438	100.0%	1.77 [1.28, 2.44]	
Total events	210		147				
Heterogeneity: Tau <sup>2</sup> = 0.03	; Chi <sup>2</sup> = 5.17, df	= 4 (P =	0.27); I <sup>2</sup>	= 23%			
Test for overall effect: Z = 3	3.49 (P = 0.0005)	)					
3.1.2 Medium term							
COPES 2010	34	80	19	77	100.0%	2.26 [1.14, 4.46]	
Subtotal (95% CI)		80		77	100.0%	2.26 [1.14, 4.46]	
Total events	34		19				
Heterogeneity: Not applica	able						
	2.34 (P = 0.02)						
restion overall ellect. Z = 2							
restion overall ellect. Z = 2							

222x97mm (96 x 96 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.




Figure showing the adjudication of risk of bias in included trials. Risk of bias independently adjudicated by PJT and HB using Cochrane Review Manager 5.3. Final risk of bias determined by consensus between the two raters.

# eSupplement 2. Forest plot showing anxiety symptoms in collaborative care studies versus usual care or waiting list control (short term)

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI
CODIACS 2013	-7.06	9.6081	62	-3.92	8.3874	62	20.7%	-0.35 [-0.70, 0.01]	
COPES 2010	-2.38	4.0892	80	0.13	3.8331	77	24.2%	-0.63 [-0.95, -0.31]	<b>_</b>
MOSAIC 2014	-4.28	1.7945	92	-3.87	1.7945	91	28.0%	-0.23 [-0.52, 0.06]	
SUCCEED 2011	-4.16	5.2042	90	-2.83	5.2852	85	27.1%	-0.25 [-0.55, 0.05]	
Total (95% CI)			324			315	100.0%	-0.36 [-0.54, -0.17]	◆
Heterogeneity: Tau <sup>2</sup>	= 0.01: C	hi² = 4.02	. df = 3	(P = 0.3)	26); I <b>ř</b> = 2	5%			-1 -0.5 0 0.5 1

CI, confidence interval; IV, inverse variance;

# eSupplement 3. Forest plot showing mental quality of life symptoms in collaborative care studies versus usual care or waiting list control (short term)

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
vpass The Blues 2009			150	3.6		152	28.6%	0.26 [0.03, 0.49]	
ODIACS 2013	7	13.1564	65	5.79	14.0076	70	16.3%	0.09 [-0.25, 0.43]	<b>_</b>
OPES 2010	3.32	11.4735	59	3.78	12.5511	65	15.2%	-0.04 [-0.39, 0.31]	
IOSAIC 2014	11.21	12.2164	92	5.53	12.2164	91	20.1%	0.46 [0.17, 0.76]	
SUCCEED 2011	12.18	15.2784	90	8.26	13.1204	85	19.7%	0.27 [-0.02, 0.57]	
otal (95% CI)			456			463	100.0%	0.23 [0.08, 0.38]	◆
Heterogeneity: Tau <sup>2</sup> = 0.01	I∶Chi <b>²</b> =	5.45. df = -	4 (P = 0	.24): <b> </b> ²÷	= 27%				-1 -0.5 0 0.5 1

Cl, confidence interval; IV, inverse variance;

# eSupplement 4. Forest plot showing physical quality of life symptoms in collaborative care studies versus usual care or waiting list control (short term)

Chudu on Cubanous		perimenta			Control	Tetal		Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	
Bypass The Blues 2009	12.8	9.798	150	11.1	9.8631	152	30.5%	0.17 [-0.05, 0.40]	+	
CODIACS 2013	-0.78	10.735	65	-1.04	11.5752	70	15.4%	0.02 [-0.31, 0.36]		
COPES 2010	1.44	9.7261	65	-1.01	9.8875	65	14.8%	0.25 [-0.10, 0.59]		
MOSAIC 2014	4.88	9.8353	92	2.57	9.8353	91	20.0%	0.23 [-0.06, 0.52]		
SUCCEED 2011	2.14	11.6975	90	3.88	12.7958	85	19.3%	-0.14 [-0.44, 0.16]		
Fotal (95% CI)			462			463	100.0%	0.11 [-0.03, 0.25]	-	
Heterogeneity: Tau <sup>2</sup> = 0.00	D: Chi≊ =	4 62 df= 4	1 (P = 0	i 33)· I≊a	= 13%				-1 -0.5 0	0.5


CI, confidence interval; IV, inverse variance;

## eSupplement 5. Forest plot showing healthcare costs in collaborative care studies versus usual care or waiting list control (short term and medium term)

	E	xperimental			Control			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
5.3.1 Short Term									
CODIACS 2013	4,289	8,026.8694	73	4,358	8,026.8694	77	48.9%	-0.01 [-0.33, 0.31]	<b>_</b>
COPES 2010 Subtotal (95% CI)	1,857	5,471.3714	80 153	2,797	5,471.3714	77 154	51.1% <b>100.0%</b>	-0.17 [-0.48, 0.14] - <b>0.09 [-0.32, 0.13]</b>	
Heterogeneity: Tau <sup>2</sup> = 0.00 Test for overall effect: Z = 0 5.3.2 Medium Term			= 0.48)	; I* = U%					
Bypass The Blues 2009 Subtotal (95% CI)	19,279	31,369	90 90	17,522	21,072	99 <b>99</b>	100.0% <b>100.0%</b>	0.07 [-0.22, 0.35] 0.07 [-0.22, 0.35]	
Heterogeneity: Not applica	ble								
Test for overall effect: Z = 0	).45 (P = 0	0.65)							
									-1 -0.5 0 0.5 1 Favours Collab. Care Favours Control

Cl, confidence interval; IV, inverse variance;

## eSupplement 6. Forest plot showing the risk ratio for acute coronary syndrome post intervention in collaborative care studies versus usual care or waiting list control (short term)



*CI*, confidence interval; *IV*, inverse variance;


Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## eSupplement 7. Forest plot showing the risk ratio for coronary revascularization post intervention in collaborative care studies versus usual care or waiting list control (short term)

	Experim	ental	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Bypass The Blues 2009	3	150	5	152	42.9%	0.61 [0.15, 2.50]	
CODIACS 2013	6	73	4	77	57.1%	1.58 [0.47, 5.38]	
Total (95% CI)		223		229	100.0%	1.05 [0.42, 2.65]	
Total events	9		9				
Heterogeneity: Tau <sup>z</sup> = 0.00; Chi <sup>z</sup> = 1.01, df = 1 (P = 0.32); i <sup>z</sup> = 19 Test for overall effect: Z = 0.10 (P = 0.92)							0.1 0.2 0.5 1 2 5 10 Favours Collab. Care Favours Control


CI, confidence interval; IV, inverse variance;

### eSupplement 8. Forest plot showing the risk ratio for heart failure post intervention in collaborative care studies versus usual care or waiting list control (short term)



CI, confidence interval; IV, inverse variance;

#### eSupplement 9. Forest plot showing the risk ratio for stroke post intervention in collaborative care studies versus usual care or waiting list control (short term)



CI, confidence interval; IV, inverse variance;

## eSupplement 10. Forest plot showing the risk ratio for cardiac-cause hospital admission post intervention in collaborative care studies versus usual care or waiting list control (short term)

	Experim	Contr	Control		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Bypass The Blues 2009	23	150	28	152	21.2%	0.83 [0.50, 1.38]	— <b></b>
CODIACS 2013	17	73	16	77	16.6%	1.12 [0.61, 2.05]	_ <b>_</b>
COPES 2010	5	80	16	77	8.0%	0.30 [0.12, 0.78]	
MOSAIC 2014	29	91	30	92	26.3%	0.98 [0.64, 1.49]	-+-
SUCCEED 2011	32	88	30	84	27.8%	1.02 [0.68, 1.52]	-+-
Total (95% CI)		482		482	100.0%	0.89 [0.66, 1.19]	•
Total events	106		120				
Heterogeneity: Tau <sup>2</sup> = 0.04	4; Chi <sup>2</sup> = 6.1	16, df =	4 (P = 0.1	9); I <sup>z</sup> =	35%		
Test for overall effect: $Z = 1$	0.79 (P = 0.	43)					0.01 0.1 1 10 100 Favours Collab. Care Favours Control

CI, confidence interval; IV, inverse variance;

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### eSupplement 11. Forest plot of sensitivity analysis showing depression symptoms post intervention in collaborative care studies versus usual care or waiting list control (short term)

Study or Subgroup	Collaborative Care Mean SD Total Mea	Control n SD Tota	al Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
1.8.1 Treatment Initiated	Before Confirming Chronicity				
MOSAIC 2014	-8.06 6.9364 91 -6.0		2 27.3%	-0.29 [-0.59, -0.00]	
SUCCEED 2011	-8.67 7.1618 90 -6.			-0.27 [-0.56, 0.03]	
TrueBlue 2013 Subtotal (95% CI)	-3.6 10.245 164 -2.1 <b>345</b>	6 10.8747 14	6 46.6% 3 100.0%	-0.09 [-0.32, 0.13] - <b>0.19 [-0.35, -0.04]</b>	
	; Chi² = 1.44, df = 2 (P = 0.49); l <sup>2</sup>		5 100.0%	-0.19 [-0.35, -0.04]	
Test for overall effect: Z = 2		- 0 %			
	After Confirming Chronicity				_
Bypass The Blues 2009	-7.6 7.3485 150 -4.9			-0.42 [-0.65, -0.19]	
CODIACS 2013 COPES 2010	-10.1 8.1434 73 -6.1 -5.7 8.5378 80 -1.1			-0.42 [-0.75, -0.10] -0.45 [-0.76, -0.13]	
Subtotal (95% CI)	-0.7 0.0070 00 -1.3 303		6 100.0%	-0.43 [-0.59, -0.27]	•
	; Chi <sup>2</sup> = 0.02, df = 2 (P = 0.99); P				•
Test for overall effect: Z = 5					
					-t
Test for subgroup differen	ces: Chi² = 4.26, df = 1 (P = 0.04	) 17-76.5%			-1 -0.5 0 0.5 Favours Collab. Care Favours Control
restion subgroup unleren	tes. Chir = 4.20, ui = 1 (r = 0.04	s), I' = 70.5%			

## eSupplement 12. Forest plot of sensitivity analysis showing depression remission post intervention in collaborative care studies versus usual care or waiting list control (short term)

Chudu an Cult	Collaborative		Contr		Maria La	Odds Ratio	Odds Ratio
Study or Subgroup 1.9.1 Treatment Initiated	Events Poforo Confirm			lotal	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
MOSAIC 2014	19	111 <b>9 C1110</b> 55	9	47	31.7%	2 22 [0 00 6 60]	
MUSAIC 2014 SUCCEED 2011	19	55 90	9 37	47 85	31.7% 68.3%	2.23 [0.89, 5.56] 1.24 [0.68, 2.25]	
SUCCEED 2011 Subtotal (95% CI)	44	90 145	37		100.0%	1.24 [0.88, 2.25] 1.49 [0.88, 2.55]	
Total events	63	145	46	102	.00.0/0	1110 [0100] 2100]	
Heterogeneity: Tau <sup>2</sup> = 0.0:		'= 1 (P =		- 10%			
Test for overall effect: Z =		- 10 -	0.20/,1	- 10 %			
1.9.2 Treatment Initiated	After Confirmin	a Chroni	city				
Bypass The Blues 2009	75	150	45	152	42.5%	2.38 [1.48, 3.82]	
CODIACS 2013	38	73	37	77	29.9%	1.17 [0.62, 2.23]	<b>_</b>
COPES 2010	34	80	19	77	27.6%	2.26 [1.14, 4.46]	<b>_</b>
Subtotal (95% CI)		303			100.0%	1.90 [1.23, 2.93]	
Total events	147		101				
Heterogeneity: Tau <sup>2</sup> = 0.0	ð; Chi <b>²</b> = 3.26, df	= 2 (P =	0.20); l² :	= 39%			
Test for overall effect: Z =							
							Favours Control Favours Collab. Ca
Test for subgroup differer	ices: Chi² = 0.46	, df = 1 (F	° = 0.50),	, <b>I<sup>2</sup> =</b> 09	%		

### eSupplement 13. Forest plot showing the odds ratio for anti-depressant therapy post intervention in collaborative care studies versus usual care or waiting list control (short term)

	Collaborative	Care	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events Total		Events Total		Weight	IV, Random, 95% CI	IV, Random, 95% CI
Bypass The Blues 2009	55	126	40	127	19.4%	1.68 [1.01, 2.82]	
CODIACS 2013	37	73	28	77	16.5%	1.80 [0.94, 3.45]	
COPES 2010	38	80	23	77	16.4%	2.12 [1.10, 4.09]	<b>_</b>
MOSAIC 2014	36	53	28	46	13.3%	1.36 [0.60, 3.11]	
SUCCEED 2011	47	70	39	68	15.7%	1.52 [0.76, 3.04]	
TrueBlue 2013	34	162	36	113	18.7%	0.57 [0.33, 0.98]	
Total (95% CI)		564		508	100.0%	1.38 [0.91, 2.10]	
Total events	247		194				
Heterogeneity: Tau <sup>2</sup> = 0.17	7; Chi <sup>z</sup> = 13.00,	df = 5 (P	= 0.02);1	<b>≈</b> = 629	6		0.2 0.5 1 2 5
Test for overall effect: Z = 1							0.2 0.5 1 2 Favours Control Favours Collab. Care

CI, confidence interval; IV, inverse variance;

### eSupplement 14. Forest plot showing the odds ratio for psychotherapy post intervention in collaborative care studies versus usual care or waiting list control (short term)

04 J	Collaborative		Conti			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	vveight	IV, Random, 95% CI	IV, Random, 95% CI
Bypass The Blues 2009	5	126	7	127	14.6%	0.71 [0.22, 2.29]	
CODIACS 2013	48	73	14	77	17.4%	8.64 [4.06, 18.37]	
COPES 2010	31	80	9	77	16.9%	4.78 [2.09, 10.94]	<b>_</b>
MOSAIC 2014	40	53	34	46	16.4%	1.09 [0.44, 2.69]	<b>_</b>
SUCCEED 2011	14	70	19	68	17.2%	0.64 [0.29, 1.42]	
TrueBlue 2013	37	162	11	109	17.6%	2.64 [1.28, 5.43]	—•—
Total (95% CI)		564		504	100.0%	2.01 [0.85, 4.76]	
Total events	175		94				
Heterogeneity: Tau <sup>2</sup> = 0.9	7; Chi <sup>2</sup> = 31.40,	df = 5 (P	< 0.0000	(1); I² =	84%		0.05 0.2 1 5 20

Cl, confidence interval; IV, inverse variance;

2
-
3
3 4 5 6 7 8
7
5
6
-
1
8
~
9
10
44
11
12
40
13
14
15
10
16
17
17
$8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 27 \\ 28 \\ 29 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 37 \\ 38 \\ 39 \\ 39 \\ 31 \\ 31 \\ 31 \\ 31 \\ 31 \\ 31$
10
13
20
21
<u> </u>
22
23
20
24
25
20
26
27
~
28
29
20
30
31
22
32
33
21
54
35
36
50
37
38
00
39
40
44
41 42
42
43
43
44
45
40
46
47
71
48
49
50
51
52
53
E 4
54
55
56
57
57 58

1

GRADE Item	MACE	Depression	Anxiety	Mental	Physical	Cost
	Endpoint			QOL	QOL	Effectiveness
Risk of bias	Serious (-1)					
Inconsistency	No	No	No	No	No	No
Indirectness	No	No	No	No	No	No
Imprecision	No	No	No	No	No	No
Publication bias	Undetected	Undetected	Undetected	Undetected	Undetected	Undetected
Large effect	No	No	No	No	No	No
Plausible confounding would change the effect	No	No	No	No	No	No
Dose response gradient	No	No	No	No	No	No
Quality of evidence	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate

#### eSupplement 15. GRADE assessment of each endpoint

GRADE assessment made using GRADE profiler 3.6.1 [27]

MACE included myocardial infarction, coronary revascularization procedure, incident heart failure, stroke

MACE, major adverse cardiac events; QOL, quality of life

## **PRISMA 2009 Checklist**

Section/topic	#	Checklist item	Reported on page #
TITLE	·		
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6 and abstract
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6 - 7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	eSupplement
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	8
5	-	t no hoc imd.naqoįmd\\taphi moni babaolowod. 2105. December 2015. Downloaded from http://mdiopen.2102-nadojmd/ Enseignement Superieur (BEBA) Protected by כמצעומלים למלומין אוליאניט אוליגעוליא אוליגעולים לעפאנאט אוליגעולים אוליגעולים אוליגעולים לפרוחסוס אוליגעולים אוליגעולים אוליגעולים אוליגעולים אוליגעולים אוליגעולים אוליגעולים אוליגעולים אוליגעולים אוליגעולים ל היארין אוליגעולים אוליגעוליעולים אוליגעולים אוליגעולים אוליגעולים אוליגעולים אוליגעוליגעולים אוליגעולים אוליגעולים אוליגעולים אוליגעוליגעולים אוליגעולים אוליגעולים אוליגעולים אוליגעוליגעולים אוליגעוליגעוליגעוליגעולים אוליגעוליגעוליגעוליגעוליגעוליגעוליגעוליגע	open: firsi

BMJ Open



## **PRISMA 2009 Checklist**

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	10
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	NA
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8, Fig 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8-10, Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10, eSupplement 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Fig 2 - 4
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10 - 13 Fig 2 – 4;
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10, eSupplement 1
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	11-13, eSupplement 2-14
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13-16
FUNDING	1		
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17

48 I ab aupidgrapolidig aprogram 2015, 2025, 21 anul. no lmoo.imd.naqojmd/l;q11d mont babsolnword. 215. Downloaded from http://dingrapolidid.ac.int.com/ on June 13, 2025 at Agence Bibliographique de I 84

10

Page 49 of 49

BMJ Open



## **PRISMA 2009 Checklist**

<sup>3</sup> From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.

3 4	From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
5	For more information, visit: <u>www.prisma-statement.org</u> .
6	Page 2 of 2
7	
8	
9	
10	
11 12	
13	
14	
15	
16	
17	
18	
19	
20	
21 22	
23	
24	
25	
26	
27	
28 29	
29 30	
31	
32	
33	
34	
35	
36	de la 137 Hournal presentation de la contraction
37 38	
39	
40	
41	
42	
43	
44	
45	
46 47	
	BMJ Open: first published as 13, 2025 at Agence Bibliographic 2015. Downloaded from http://bmjopen.bml.com/ on June 13, 2025 at Agence Bibliographique de l
<u>1</u> 0	